1175 
‘‘SEC. 399OO–2. GRANTS. 
‘‘(a) IN GENERAL.—The Secretary may award grants 
to, or enter into contracts or cooperative agreements with, 
States, political subdivisions of States, territories, Indian 
Tribes, or nonprofit entities that have special expertise re-
lating to hepatitis B, hepatitis C, or both, to carry out 
activities under this part. 
‘‘(b) APPLICATION.—To be eligible for a grant, con-
tract, or cooperative agreement under subsection (a), an 
entity shall prepare and submit to the Secretary an appli-
cation at such time, in such manner, and containing such 
information as the Secretary may require. 
‘‘SEC. 399OO–3. AUTHORIZATION OF APPROPRIATIONS. 
‘‘There are authorized to be appropriated to carry out 
this part $90,000,000 for fiscal year 2025, $110,000,000 
for fiscal year 2026, $130,000,000 for fiscal year 2027, 
and $150,000,000 for fiscal year 2028.’’. 
SEC. 7102. LIVER CANCER AND DISEASE PREVENTION, 
AWARENESS, 
AND 
PATIENT 
TRACKING 
GRANTS. 
Subpart I of part D of title III of the Public Health 
Service Act (42 U.S.C. 254b et seq.) is amended by adding 
at the end the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01175
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1176 
‘‘SEC. 330Q. LIVER CANCER AND DISEASE PREVENTION, 
AWARENESS, 
AND 
PATIENT 
TRACKING 
GRANTS. 
‘‘(a) PREVENTION INITIATIVE GRANT PROGRAM.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, may award grants and 
enter into cooperative agreements with entities for 
the purpose of expanding and supporting— 
‘‘(A) prevention activities (including pro-
viding screenings, vaccinations, or other pre-
ventative interventions) for conditions known to 
increase an individual’s risk of developing a 
major liver disease, such as liver cancer, hepa-
titis B, hepatitis C, nonalcoholic fatty liver dis-
ease, nonalcoholic steatohepatitis, and cirrhosis 
of the liver; 
‘‘(B) activities relating to detection and 
provision of guidance for individuals at high 
risk for contracting liver cancer and other liver 
diseases; and 
‘‘(C) viral hepatitis surveillance to provide 
for timely and accurate information regarding 
progress to eliminate viral hepatitis. 
‘‘(2) REPORT.—An entity that receives a grant 
or cooperative agreement under paragraph (1) shall 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01176
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1177 
submit to the Secretary, at a time specified by the 
Secretary, a report describing each activity carried 
out pursuant to such paragraph and evaluating the 
effectiveness of such activity in promoting prevention 
and treatment of liver cancer and other liver dis-
eases. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $90,000,000 for 
each of fiscal years 2024 through 2028. 
‘‘(b) AWARENESS INITIATIVE GRANT PROGRAM.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, may award grants to eligi-
ble entities for the purpose of raising awareness for 
liver cancer and other liver diseases, which may in-
clude the production, dissemination, and distribution 
of informational materials targeted towards commu-
nities and populations with a higher risk for devel-
oping liver cancer and other liver diseases. 
‘‘(2) ELIGIBLE ENTITIES.—To be eligible to re-
ceive a grant under paragraph (1), an entity shall 
submit to the Secretary an application, at such time, 
in such manner, and containing such information as 
the Secretary may require, including a description of 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01177
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1178 
how the entity, in disseminating information on liver 
cancer and other liver diseases pursuant to para-
graph (1), will— 
‘‘(A) with respect to any community or 
population, consult with members of such com-
munity or population and provide such informa-
tion in a manner that is culturally and linguis-
tically appropriate for such community or popu-
lation; 
‘‘(B) highlight the range of preventative 
measures and treatments available for liver can-
cer and other liver diseases; 
‘‘(C) integrate information on available 
hepatitis B and hepatitis C testing programs 
into any liver cancer presentations carried out 
by the entity; and 
‘‘(D) address communities and populations 
with a higher risk for contracting liver cancer 
and other liver diseases. 
‘‘(3) PREFERENCE.—In awarding grants under 
paragraph (1), the Secretary shall give preference to 
entities that— 
‘‘(A) work with a Federally qualified 
health center; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01178
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1179 
‘‘(B) are community-based organizations; 
or 
‘‘(C) serve communities and populations 
with a higher risk for contracting liver cancer 
and other liver diseases. 
‘‘(4) REPORT.—An entity that receives a grant 
under paragraph (1) shall submit to the Secretary, 
at a time specified by the Secretary, a report de-
scribing each activity carried out pursuant to such 
paragraph and evaluating the effectiveness of such 
activity in raising awareness for liver cancer and 
other liver diseases. 
‘‘(5) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $10,000,000 for 
each of fiscal years 2025 through 2029.’’. 
Subtitle C—Acquired Bone Marrow 
Failure Diseases 
SEC. 7201. ACQUIRED BONE MARROW FAILURE DISEASES. 
(a) NATIONAL ACQUIRED BONE MARROW FAILURE 
DISEASE REGISTRY.—Title III of the Public Health Serv-
ice Act (42 U.S.C. 241 et seq.) is amended by inserting 
after section 317W, as added by section 1009, the fol-
lowing: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01179
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1180 
‘‘SEC. 317X. NATIONAL ACQUIRED BONE MARROW FAILURE 
DISEASE REGISTRY. 
‘‘(a) ESTABLISHMENT OF REGISTRY.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the date of the enactment of this section, the 
Secretary, acting through the Director of the Cen-
ters for Disease Control and Prevention, shall— 
‘‘(A) develop a system to collect data on 
acquired bone marrow failure diseases; and 
‘‘(B) establish and maintain a national and 
publicly available registry, to be known as the 
National Acquired Bone Marrow Failure Dis-
ease Registry, in accordance with paragraph 
(3). 
‘‘(2) RECOMMENDATIONS
OF
ADVISORY
COM-
MITTEE.—In carrying out this subsection, the Sec-
retary shall take into consideration the recommenda-
tions of the Advisory Committee on Acquired Bone 
Marrow Failure Diseases established under sub-
section (b). 
‘‘(3) PURPOSES OF REGISTRY.—The National 
Acquired Bone Marrow Failure Disease Registry 
shall— 
‘‘(A) identify the incidence and prevalence 
of acquired bone marrow failure diseases in the 
United States; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01180
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1181 
‘‘(B) be used to collect and store data on 
acquired bone marrow failure diseases, includ-
ing data concerning— 
‘‘(i) the age, race or ethnicity, general 
geographic location, sex, and family history 
of individuals who are diagnosed with ac-
quired bone marrow failure diseases, and 
any other characteristics of such individ-
uals determined appropriate by the Sec-
retary; 
‘‘(ii) the genetic and environmental 
factors that may be associated with devel-
oping acquired bone marrow failure dis-
eases; 
‘‘(iii) treatment approaches for deal-
ing with acquired bone marrow failure dis-
eases; 
‘‘(iv) outcomes for individuals treated 
for acquired bone marrow failure diseases, 
including outcomes for recipients of stem 
cell therapeutic products as contained in 
the database established pursuant to sec-
tion 379A; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01181
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1182 
‘‘(v) any other factors pertaining to 
acquired bone marrow failure diseases de-
termined appropriate by the Secretary; and 
‘‘(C) be made available— 
‘‘(i) to the general public; and 
‘‘(ii) to researchers to facilitate fur-
ther research into the causes of, and treat-
ments for, acquired bone marrow failure 
diseases in accordance with standard prac-
tices of the Centers for Disease Control 
and Prevention. 
‘‘(b) ADVISORY COMMITTEE.— 
‘‘(1) ESTABLISHMENT.—Not later than 6 
months after the date of the enactment of this sec-
tion, the Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, 
shall establish an advisory committee, to be known 
as the Advisory Committee on Acquired Bone Mar-
row Failure Diseases. 
‘‘(2) MEMBERS.—The members of the Advisory 
Committee on Acquired Bone Marrow Failure Dis-
eases shall be appointed by the Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, and shall include at least 
one representative from each of the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01182
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1183 
‘‘(A) A national patient advocacy organiza-
tion with experience advocating on behalf of pa-
tients suffering from acquired bone marrow 
failure diseases. 
‘‘(B) The National Institutes of Health, in-
cluding at least one representative from each 
of— 
‘‘(i) the National Cancer Institute; 
‘‘(ii) the National Heart, Lung, and 
Blood Institute; and 
‘‘(iii) the Office of Rare Diseases. 
‘‘(C) The Centers for Disease Control and 
Prevention. 
‘‘(D) Clinicians with experience in— 
‘‘(i) diagnosing or treating acquired 
bone marrow failure diseases; or 
‘‘(ii) medical data registries. 
‘‘(E) Epidemiologists who have experience 
with data registries. 
‘‘(F) Publicly or privately funded research-
ers who have experience researching acquired 
bone marrow failure diseases. 
‘‘(G) The entity operating the C.W. Bill 
Young Cell Transplantation Program estab-
lished pursuant to section 379 and the entity 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01183
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1184 
operating the C.W. Bill Young Cell Transplan-
tation Program Outcomes Database. 
‘‘(3) RESPONSIBILITIES.—The Advisory Com-
mittee on Acquired Bone Marrow Failure Diseases 
shall provide recommendations to the Secretary on 
the establishment and maintenance of the National 
Acquired Bone Marrow Failure Disease Registry, in-
cluding recommendations on the collection, mainte-
nance, and dissemination of data. 
‘‘(4) PUBLIC
AVAILABILITY.—The Secretary 
shall make the recommendations of the Advisory 
Committee on Acquired Bone Marrow Failure Dis-
ease publicly available. 
‘‘(c) GRANTS.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion, may award grants to, and enter into contracts and 
cooperative agreements with, public or private nonprofit 
entities for the management of, as well as the collection, 
analysis, and reporting of data to be included in, the Na-
tional Acquired Bone Marrow Failure Disease Registry. 
‘‘(d) DEFINITION.—In this section, the term ‘ac-
quired bone marrow failure disease’ means— 
‘‘(1) myelodysplastic syndromes; 
‘‘(2) aplastic anemia; 
‘‘(3) paroxysmal nocturnal hemoglobinuria; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01184
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1185 
‘‘(4) pure red cell aplasia; 
‘‘(5) acute myeloid leukemia that has pro-
gressed from myelodysplastic syndromes; or 
‘‘(6) large granular lymphocytic leukemia. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$3,000,000 for each of fiscal years 2025 through 2029.’’. 
(b) PILOT STUDIES THROUGH THE AGENCY FOR 
TOXIC SUBSTANCES AND DISEASE REGISTRY.— 
(1) PILOT STUDIES.—The Secretary of Health 
and Human Services, acting through the Director of 
the Agency for Toxic Substances and Disease Reg-
istry, shall conduct pilot studies to determine which 
environmental factors, including exposure to toxins, 
may cause acquired bone marrow failure diseases. 
(2) COLLABORATION WITH THE RADIATION IN-
JURY TREATMENT NETWORK.—In carrying out the 
directives of this section, the Secretary of Health 
and Human Services may collaborate with the Radi-
ation Injury Treatment Network of the C.W. Bill 
Young Cell Transplantation Program established 
pursuant to section 379 of the Public Health Service 
Act (42 U.S.C. 274k) to— 
(A) augment data for the pilot studies au-
thorized by this section; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01185
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1186 
(B) access technical assistance that may be 
provided by the Radiation Injury Treatment 
Network; or 
(C) perform joint research projects. 
(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $1,000,000 for each of fiscal years 
2025 through 2029. 
(c) MINORITY-FOCUSED PROGRAMS ON ACQUIRED 
BONE MARROW FAILURE DISEASES.—Title XVII of the 
Public Health Service Act (42 U.S.C. 300u et seq.) is 
amended by inserting after section 1707A the following: 
‘‘SEC. 
1707B. 
MINORITY-FOCUSED 
PROGRAMS 
ON 
AC-
QUIRED BONE MARROW FAILURE DISEASE. 
‘‘(a) INFORMATION AND REFERRAL SERVICES.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the date of the enactment of this section, the 
Secretary, acting through the Deputy Assistant Sec-
retary for Minority Health, shall establish and co-
ordinate outreach and informational programs tar-
geted to minority populations affected by acquired 
bone marrow failure diseases. 
‘‘(2) PROGRAM
REQUIREMENTS.—Minority-fo-
cused outreach and informational programs author-
ized by this section at the National Minority Health 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01186
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1187 
Resource Center supported under section 1707(b)(8) 
(including by means of the Center’s website, through 
appropriate locations such as the Center’s knowledge 
center, and through appropriate programs such as 
the Center’s resource persons network) and through 
minority health consultants located at each Depart-
ment of Health and Human Services regional of-
fice— 
‘‘(A) shall make information about treat-
ment options and clinical trials for acquired 
bone marrow failure diseases publicly available; 
and 
‘‘(B) shall provide referral services for 
treatment options and clinical trials. 
‘‘(b) HISPANIC AND ASIAN-AMERICAN AND PACIFIC 
ISLANDER OUTREACH.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Deputy Assistant Secretary for Minority 
Health, shall undertake a coordinated outreach ef-
fort to connect Hispanic, Asian-American, and Pa-
cific Islander communities with comprehensive serv-
ices focused on treatment of, and information about, 
acquired bone marrow failure diseases. 
‘‘(2) COLLABORATION.—In carrying out this 
subsection, the Secretary may collaborate with public 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01187
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1188 
health agencies, nonprofit organizations, community 
groups, and online entities to disseminate informa-
tion about treatment options and clinical trials for 
acquired bone marrow failure diseases. 
‘‘(c) GRANTS AND COOPERATIVE AGREEMENTS.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the date of the enactment of this section, the 
Secretary, acting through the Deputy Assistant Sec-
retary for Minority Health, shall award grants to, or 
enter into cooperative agreements with, entities to 
perform research on acquired bone marrow failure 
diseases. 
‘‘(2) REQUIREMENT.—Grants and cooperative 
agreements authorized by this subsection shall be 
awarded or entered into on a competitive, peer-re-
viewed basis. 
‘‘(3) SCOPE OF RESEARCH.—Research funded 
under this subsection shall examine factors affecting 
the incidence of acquired bone marrow failure dis-
eases in minority populations. 
‘‘(d) DEFINITION.—In this section, the term ‘ac-
quired bone marrow failure disease’ has the meaning given 
to such term in section 317X(d). 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01188
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1189 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$2,000,000 for each of fiscal years 2025 through 2029.’’. 
(d) DIAGNOSIS AND QUALITY OF CARE FOR AC-
QUIRED BONE MARROW FAILURE DISEASES.— 
(1) GRANTS.—The Secretary of Health and 
Human Services, acting through the Director of the 
Agency for Healthcare Research and Quality, shall 
award grants to entities to improve diagnostic prac-
tices and quality of care with respect to patients 
with acquired bone marrow failure diseases. 
(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $2,000,000 for each of fiscal years 
2025 through 2029. 
(e) DEFINITION.—In this section, the term ‘‘acquired 
bone marrow failure disease’’ has the meaning given such 
term in section 317X(d) of the Public Health Service Act, 
as added by subsection (a). 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01189
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1190 
Subtitle 
D—Cardiovascular 
Dis-
ease, Chronic Disease, Obesity, 
and Other Disease Issues 
SEC. 7301. GUIDELINES FOR DISEASE SCREENING FOR MI-
NORITY PATIENTS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services (in this section referred to as the ‘‘Sec-
retary’’), acting through the Director of the Agency for 
Healthcare Research and Quality, shall convene a series 
of meetings to develop guidelines for disease screening for 
minority patient populations that have a higher than aver-
age risk for many chronic diseases and cancers. 
(b) PARTICIPANTS.—In convening meetings under 
subsection (a), the Secretary shall ensure that meeting 
participants include representatives of— 
(1) professional societies and associations; 
(2) minority health organizations; 
(3) health care researchers and providers, in-
cluding those with expertise in minority health; 
(4) Federal health agencies, including the Of-
fice of Minority Health, the National Institute on 
Minority Health and Health Disparities, and the 
National Institutes of Health; and 
(5) other experts as the Secretary determines 
appropriate. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01190
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1191 
(c) DISEASES.—Screening guidelines for minority 
populations shall be developed as appropriate under sub-
section (a) for— 
(1) hypertension; 
(2) hypercholesterolemia; 
(3) diabetes; 
(4) cardiovascular disease; 
(5) cancers, including breast, prostate, colon, 
cervical, and lung cancer; 
(6) other pulmonary problems including sleep 
apnea; 
(7) asthma; 
(8) kidney diseases; 
(9) eye diseases and disorders, including glau-
coma; 
(10) HIV/AIDS and sexually transmitted infec-
tions; 
(11) uterine fibroids; 
(12) autoimmune diseases, including lupus; 
(13) mental health conditions; 
(14) dental health conditions and oral diseases, 
including oral cancer; 
(15) environmental and related health illnesses 
and conditions; 
(16) sickle cell disease and sickle cell trait; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01191
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1192 
(17) violence and injury prevention and control; 
(18) genetic and related conditions; 
(19) heart disease and stroke; 
(20) tuberculosis; 
(21) chronic obstructive pulmonary disease; 
(22) musculoskeletal diseases, arthritis, and 
obesity; and 
(23) other diseases determined appropriate by 
the Secretary. 
(d) DISSEMINATION.—Not later than 2 years after 
the date of enactment of this Act, the Secretary shall pub-
lish and disseminate to health care provider organizations 
the guidelines developed under subsection (a). 
(e) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of fiscal years 
2025 through 2029. 
SEC. 7302. CDC WISEWOMAN SCREENING PROGRAM. 
Section 1509 of the Public Health Service Act (42 
U.S.C. 300n–4a) is amended— 
(1) in subsection (a)— 
(A) by striking the heading and inserting 
‘‘IN GENERAL.—’’; and 
(B) in the matter preceding paragraph (1), 
by striking ‘‘may make grants’’ and all that fol-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01192
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1193 
lows through ‘‘purpose’’ and inserting the fol-
lowing: ‘‘may make grants to such States for 
the purpose’’; and 
(2) in subsection (d)(1), by striking ‘‘there are 
authorized’’ and all that follows through the period 
and inserting ‘‘there are authorized to be appro-
priated 
$23,000,000 
for 
fiscal 
year 
2025, 
$25,300,000 for fiscal year 2026, $27,800,000 for 
fiscal year 2027, $30,800,000 for fiscal year 2028, 
and $34,000,000 for fiscal year 2029.’’. 
SEC. 7303. REPORT ON CARDIOVASCULAR CARE FOR 
WOMEN AND MINORITIES. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.), as amended by section 
5201(c)(3), is amended by adding at the end the following: 
‘‘SEC. 399V–10. REPORT ON CARDIOVASCULAR CARE FOR 
WOMEN AND MINORITIES. 
‘‘Not later than September 30, 2024, and annually 
thereafter, the Secretary shall prepare and submit to Con-
gress a report on the quality of and access to care for 
women and minorities with heart disease, stroke, and 
other cardiovascular diseases. The report shall contain rec-
ommendations for eliminating disparities in, and improv-
ing the treatment of, heart disease, stroke, and other car-
diovascular diseases in women, racial and ethnic minori-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01193
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1194 
ties, those for whom English is not their primary lan-
guage, and individuals with disabilities.’’. 
SEC. 7304. GAO REPORT ON STRUCTURAL AND SYSTEMIC 
FACTORS 
THAT 
PERPETUATE 
CARDIO-
VASCULAR DISPARITIES. 
(a) IN GENERAL.—Not later than September 30, 
2025, the Government Accountability Office shall prepare 
and submit a report to Congress that contains the results 
of an investigation of— 
(1) the structural and systemic factors that per-
petuate disparities in access to screenings, care, and 
treatment of cardiovascular disease; and 
(2) how care navigation, including community- 
based health workers, can improve cardiovascular 
disease management and improve health outcomes. 
(b) CONTENTS.—The report shall— 
(1) identify the challenges and barriers facing 
healthcare providers and patients, which contribute 
to postponed, delayed, or suboptimal treatments for 
cardiovascular disease; 
(2) examine efforts by Federal agencies and 
Federal programs to improve screening and manage-
ment of patients with cardiovascular disease; 
(3) identify and examine existing quality meas-
ures from the Centers for Medicare & Medicaid 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01194
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1195 
Services related to cholesterol management and 
whether these measures encourage providers and 
health systems to— 
(A) perform appropriate and timely low- 
density-lipoprotein cholesterol (LDL-C) testing 
on patients at risk of a cardiovascular event; 
and 
(B) better manage patients’ elevated LDL- 
C levels in concordance with clinical guidelines 
prescribing directives to ensure patients are 
progressing 
towards 
guideline-recommended 
LDL-C levels; 
(4) identify actions the Federal government 
could take to promote collaboration with community- 
based organizations to ensure improvement in clin-
ical outcomes for patients with cardiovascular dis-
ease, including by building on recommendations 
from the Institutes of Medicine and the Centers for 
Disease Control to include community health work-
ers to improve health care delivery for underserved 
and high-risk communities; and 
(5) assess whether racial and ethnic minority 
groups, as defined in section 1707(g) of the Public 
Health Service Act (42 U.S.C. 300g–6(g)), have 
higher prior authorization rejection rates of prescrip-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01195
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1196 
tion drugs to treat or prevent cardiovascular disease 
by health insurance providers and, if so, identify the 
resulting impacts on cardiovascular disease medica-
tion adherence, morbidity, and mortality, as well as 
resulting postponed, delayed, or suboptimal treat-
ment prescribing for cardiovascular disease among 
racial and ethnic minorities. 
SEC. 7305. COVERAGE OF COMPREHENSIVE TOBACCO CES-
SATION SERVICES IN MEDICAID, CHIP, AND 
PRIVATE HEALTH INSURANCE. 
(a) REQUIRING MEDICAID COVERAGE
OF COUN-
SELING AND PHARMACOTHERAPY FOR CESSATION OF TO-
BACCO USE AND TEMPORARY ENHANCED FMAP FOR 
COVERAGE OF TOBACCO CESSATION SERVICES.—Section 
1905 of the Social Security Act (42 U.S.C. 1396d) is 
amended— 
(1) in subsection (a)(4), by striking ‘‘and (D)’’ 
and all that follows through ‘‘subsection (bb))’’ and 
inserting 
the 
following: 
‘‘(D) 
counseling 
and 
pharmacotherapy for cessation of tobacco use by in-
dividuals who are eligible under the State plan (as 
defined in subsection (bb))’’; 
(2) in subsection (b), by inserting ‘‘(bb)(2),’’ 
after ‘‘(aa),’’; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01196
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1197 
(3) by striking subsection (bb) and inserting 
the following: 
‘‘(bb) COUNSELING
AND PHARMACOTHERAPY
FOR 
CESSATION OF TOBACCO USE.— 
‘‘(1) IN GENERAL.—For purposes of this title, 
the term ‘counseling and pharmacotherapy for ces-
sation of tobacco use by individuals who are eligible 
under the State plan’ means diagnostic, therapy, 
and counseling services and pharmacotherapy (in-
cluding the coverage of prescription and nonprescrip-
tion tobacco cessation agents approved by the Food 
and Drug Administration) for the cessation of to-
bacco use by individuals who use tobacco products or 
who are being treated for tobacco use that is fur-
nished— 
‘‘(A) by or under the supervision of a phy-
sician; or 
‘‘(B) by any other health care professional 
who— 
‘‘(i) is legally authorized to furnish 
such services under State law (or the State 
regulatory mechanism provided by State 
law) of the State in which the services are 
furnished; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01197
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1198 
‘‘(ii) is authorized to receive payment 
for other services under this title or is des-
ignated by the Secretary for this purpose, 
which is recommended in the guideline entitled, 
‘Treating Tobacco Use and Dependence: 2008 
Update: A Clinical Practice Guideline’ pub-
lished by the Public Health Service in May 
2008 (or any subsequent modification of such 
guideline) or is recommended for the cessation 
of tobacco use by the United States Preventive 
Services Task Force or any additional interven-
tion approved by the Food and Drug Adminis-
tration as safe and effective in helping smokers 
quit. 
‘‘(2) TEMPORARY ENHANCED FMAP FOR COV-
ERAGE
OF
TOBACCO
CESSATION
SERVICES.—Not-
withstanding subsection (b), for calendar quarters 
occurring during the period beginning on the date of 
the enactment of this paragraph and ending 5 years 
after the date of enactment of this paragraph, the 
Federal medical assistance percentage with respect 
to amounts expended by a State for medical assist-
ance for counseling and pharmacotherapy for ces-
sation of tobacco use by individuals who are eligible 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01198
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1199 
under the State plan (as defined in paragraph (1)) 
shall be equal to 90 percent.’’. 
(b) NO COST SHARING.— 
(1) IN
GENERAL.—Subsections (a)(2) and 
(b)(2) of section 1916 of the Social Security Act (42 
U.S.C. 1396o), as amended by section 2007(d)(4), 
are each amended— 
(A) in subparagraph (B), by striking ‘‘, 
and counseling’’ and all that follows through 
‘‘section 1905(bb)(2)(A)’’; 
(B) in subparagraph (J), by striking ‘‘or’’ 
after the comma; 
(C) in subparagraph (K), by striking ‘‘; 
and’’ and inserting ‘‘, or’’; and 
(D) by adding at the end the following new 
subparagraph: 
‘‘(L) counseling and pharmacotherapy for 
cessation of tobacco use by individuals who are 
eligible under the State plan (as defined in sec-
tion 1905(bb)) and covered outpatient drugs (as 
defined in subsection (k)(2) of section 1927 and 
including nonprescription drugs described in 
subsection (d)(2) of such section) that are pre-
scribed for purposes of promoting tobacco ces-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01199
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1200 
sation in accordance with the guideline specified 
in section 1905(bb); and’’. 
(2) APPLICATION TO ALTERNATIVE COST SHAR-
ING.—Section 1916A(b)(3)(B) of the Social Security 
Act (42 U.S.C. 1396o–1(b)(3)(B)) is amended— 
(A) in clause (iii), by striking ‘‘, and coun-
seling and pharmacotherapy for cessation of to-
bacco use by pregnant women (as defined in 
section 1905(bb))’’; and 
(B) by adding at the end the following new 
clause: 
‘‘(xv) 
Counseling 
and 
pharmacotherapy for cessation of tobacco 
use by individuals who are eligible under 
the State plan (as defined in section 
1905(bb)) and covered outpatient drugs 
(as defined in subsection (k)(2) of section 
1927 and including nonprescription drugs 
described in subsection (d)(2) of such sec-
tion) that are prescribed for purposes of 
promoting tobacco cessation in accordance 
with the guideline specified in section 
1905(bb).’’. 
(c) EXCEPTION
FROM
OPTIONAL
RESTRICTION 
UNDER MEDICAID PRESCRIPTION DRUG COVERAGE.— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01200
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1201 
Section 1927(d)(2)(F) of the Social Security Act (42 
U.S.C. 1396r–8(d)(2)(F)) is amended to read as follows: 
‘‘(F) Nonprescription drugs, except, when 
recommended in accordance with the guideline 
referred to in section 1905(bb), agents ap-
proved by the Food and Drug Administration 
under the over-the-counter monograph process 
for purposes of promoting tobacco cessation.’’. 
(d) STATE MONITORING AND PROMOTING OF COM-
PREHENSIVE TOBACCO CESSATION SERVICES UNDER 
MEDICAID.—Section 1902(a) of the Social Security Act 
(42 
U.S.C. 
1396a(a)), 
as 
amended 
by 
section 
5201(c)(2)(B), is amended— 
(1) in paragraph (87), by striking ‘‘and’’ at the 
end; 
(2) in paragraph (88), by striking the period at 
the end and inserting ‘‘; and’’; and 
(3) by inserting after paragraph (88) the fol-
lowing new paragraph: 
‘‘(89) provide that the State will monitor and 
promote the use of comprehensive tobacco cessation 
services under the State plan (including conducting 
an outreach campaign to increase awareness of the 
benefits of using such services) among— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01201
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1202 
‘‘(A) individuals entitled to medical assist-
ance under the State plan who use tobacco 
products; and 
‘‘(B) clinicians and others who provide 
services to individuals entitled to medical assist-
ance under the State plan.’’. 
(e) FEDERAL
REIMBURSEMENT
FOR
OUTREACH 
CAMPAIGN.—Section 1903(a) of the Social Security Act 
(42 U.S.C. 1396b(a)) is amended— 
(1) in paragraph (6)(B), by striking ‘‘plus’’ at 
the end; 
(2) in paragraph (7), by striking the period at 
the end and inserting ‘‘; plus’’; and 
(3) by inserting after paragraph (7) the fol-
lowing new paragraph: 
‘‘(8) with respect to the development, imple-
mentation, and evaluation of an outreach campaign 
to— 
‘‘(A) increase awareness of comprehensive 
tobacco cessation services covered in the State 
plan among— 
‘‘(i) individuals who are likely to be el-
igible for medical assistance under the 
State plan; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01202
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1203 
‘‘(ii) clinicians and others who provide 
services to individuals who are likely to be 
eligible for medical assistance under the 
State plan; and 
‘‘(B) increase awareness of the benefits of 
using comprehensive tobacco cessation services 
covered in the State plan among— 
‘‘(i) individuals who are likely to be el-
igible for medical assistance under the 
State plan; and 
‘‘(ii) clinicians and others who provide 
services to individuals who are likely to be 
eligible for medical assistance under the 
State plan about the benefits of using com-
prehensive tobacco cessation services, 
for calendar quarters occurring during the pe-
riod beginning on the date of the enactment of 
this paragraph and ending on the date that is 
5 years after the date of enactment of this 
paragraph, an amount equal to 90 percent of 
the sums expended during each quarter which 
are attributable to such development, implemen-
tation, and evaluation, and for calendar quar-
ters succeeding such period, an amount equal to 
Federal medical assistance percentage deter-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01203
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1204 
mined under section 1905(b) of the sums ex-
pended during each quarter which are so attrib-
utable.’’. 
(f) NO PRIOR AUTHORIZATION FOR TOBACCO CES-
SATION DRUGS UNDER MEDICAID.—Section 1927(d) of 
the Social Security Act (42 U.S.C. 1396r–8(d)) is amend-
ed— 
(1) in paragraph (1)(A), by striking ‘‘A State’’ 
and inserting ‘‘Subject to paragraph (8), a State’’; 
and 
(2) by adding at the end the following new 
paragraph: 
‘‘(8) NO PRIOR AUTHORIZATION PROGRAMS FOR 
TOBACCO CESSATION DRUGS.—A State plan may not 
require, as a condition of coverage or payment for 
a covered outpatient drug, the approval of an agent 
to promote smoking cessation (including agents ap-
proved by the Food and Drug Administration) or to-
bacco cessation.’’. 
(g) EXCLUSION
OF ENHANCED PAYMENTS FROM 
TERRITORIAL CAPS.—Notwithstanding any other provi-
sion of law, for purposes of section 1108 of the Social Se-
curity Act (42 U.S.C. 1308), with respect to any addi-
tional amount paid to a territory as a result of the applica-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01204
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1205 
tion of section 1905(bb)(2) of the Social Security Act (42 
U.S.C. 1396d(bb)(2))— 
(1) the limitation on payments to territories 
under subsections (f) and (g) of such section 1108 
shall not apply to such additional amounts; and 
(2) such additional amounts shall be dis-
regarded in applying such subsections. 
(h) REQUIRING CHIP COVERAGE OF COUNSELING 
AND PHARMACOTHERAPY FOR CESSATION OF TOBACCO 
USE.— 
(1) IN
GENERAL.—Section 2103(c)(2) of the 
Social Security Act (42 U.S.C. 1397cc(c)(2)) is 
amended by adding at the end the following new 
subparagraph: 
‘‘(D) Counseling and pharmacotherapy for 
cessation of tobacco use by individuals who are 
eligible under the State child health plan.’’. 
(2) COUNSELING AND PHARMACOTHERAPY FOR 
CESSATION
OF
TOBACCO
USE
DEFINED.—Section 
2110(c) of the Social Security Act (42 U.S.C. 
1397jj(c)) is amended by adding at the end the fol-
lowing new paragraph: 
‘‘(10) COUNSELING
AND
PHARMACOTHERAPY 
FOR CESSATION OF TOBACCO USE.—The term ‘coun-
seling and pharmacotherapy for cessation of tobacco 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01205
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1206 
use’ means diagnostic, therapy, and counseling serv-
ices and pharmacotherapy (including the coverage of 
prescription and nonprescription tobacco cessation 
agents approved by the Food and Drug Administra-
tion) for the cessation of tobacco use by individuals 
who use tobacco products or who are being treated 
for tobacco use that are furnished— 
‘‘(A) by or under the supervision of a phy-
sician; or 
‘‘(B) by any other health care professional 
who— 
‘‘(i) is legally authorized to furnish 
such services under State law (or the State 
regulatory mechanism provided by State 
law) of the State in which the services are 
furnished; and 
‘‘(ii) is authorized to receive payment 
for other services under this title or is des-
ignated by the Secretary for this purpose, 
which is recommended in the guideline entitled, 
‘Treating Tobacco Use and Dependence: 2008 
Update: A Clinical Practice Guideline’ pub-
lished by the Public Health Service in May 
2008 (or any subsequent modification of such 
guideline) or is recommended for the cessation 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01206
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1207 
of tobacco use by the United States Preventive 
Services Task Force or any additional interven-
tion approved by the Food and Drug Adminis-
tration as safe and effective in helping smokers 
quit.’’. 
(i) NO COST SHARING.—Section 2103(e) of the So-
cial Security Act (42 U.S.C. 1397cc(e)) is amended by 
adding at the end the following new paragraph: 
‘‘(5) NO
COST
SHARING
ON
BENEFITS
FOR 
COUNSELING
AND
PHARMACOTHERAPY
FOR
CES-
SATION OF TOBACCO USE.—The State child health 
plan may not impose deductibles, coinsurance, or 
other cost sharing with respect to benefits for coun-
seling and pharmacotherapy for cessation of tobacco 
use (as defined in section 2110(c)(10)) and prescrip-
tion drugs that are covered under a State child 
health plan that are prescribed for purposes of pro-
moting tobacco cessation in accordance with the 
guideline specified in section 2110(c)(10)(B).’’. 
(j) EXCEPTION
FROM
OPTIONAL
RESTRICTION 
UNDER CHIP PRESCRIPTION DRUG COVERAGE.—Section 
2103 of the Social Security Act (42 U.S.C. 1397cc) is 
amended by adding at the end the following new sub-
section: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01207
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1208 
‘‘(g) EXCEPTION FROM OPTIONAL RESTRICTION 
UNDER CHIP PRESCRIPTION DRUG COVERAGE.—The 
State child health plan may exclude or otherwise restrict 
nonprescription drugs, except, in the case of— 
‘‘(1) pregnant women when recommended in ac-
cordance with the guideline specified in section 
2110(c)(10)(B), agents approved by the Food and 
Drug Administration under the over-the-counter 
monograph process for purposes of promoting to-
bacco cessation; and 
‘‘(2) individuals who are eligible under the 
State child health plan when recommended in ac-
cordance with the Guideline referred to in section 
2110(c)(10)(B), agents approved by the Food and 
Drug Administration under the over-the-counter 
monograph process for purposes of promoting to-
bacco cessation.’’. 
(k) STATE MONITORING AND PROMOTING OF COM-
PREHENSIVE TOBACCO CESSATION SERVICES UNDER 
CHIP.—Section 2102 of the Social Security Act (42 
U.S.C. 1397bb) is amended by adding at the end the fol-
lowing new subsection: 
‘‘(d) STATE MONITORING AND PROMOTING OF COM-
PREHENSIVE TOBACCO CESSATION SERVICES UNDER 
CHIP.—A State child health plan shall include a descrip-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01208
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1209 
tion of the procedures to be used by the State to monitor 
and promote the use of comprehensive tobacco cessation 
services under the State plan (including conducting an 
outreach campaign to increase awareness of the benefits 
of using such services) among— 
‘‘(1) individuals entitled to medical assistance 
under the State child health plan who use tobacco 
products; and 
‘‘(2) clinicians and others who provide services 
to individuals entitled to medical assistance under 
the State child health plan.’’. 
(l) FEDERAL REIMBURSEMENT
FOR CHIP COV-
ERAGE AND OUTREACH CAMPAIGN.— 
(1) IN GENERAL.—Section 2105(a) of the So-
cial Security Act (42 U.S.C. 1397ee(a)) is amended 
by adding at the end the following new paragraph: 
‘‘(5) FEDERAL
REIMBURSEMENT
FOR
CHIP 
COVERAGE
OF
COMPREHENSIVE
TOBACCO
CES-
SATION
SERVICES
AND
OUTREACH
CAMPAIGN.—In 
addition to the payments made under paragraph (1) 
for calendar quarters occurring during the period be-
ginning on the date of the enactment of this para-
graph and ending 5 years after such date, the Sec-
retary shall pay— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01209
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1210 
‘‘(A) an amount equal to 90 percent of the 
sums expended during each quarter which are 
attributable to the cost of furnishing counseling 
and pharmacotherapy for cessation of tobacco 
use by individuals who are eligible under the 
State child health plan (net of any payments 
made to the State under paragraph (1) with re-
spect to such counseling and pharmacotherapy); 
plus 
‘‘(B) an amount equal to 90 percent of the 
sums expended during each quarter which are 
attributable to the development, implementa-
tion, and evaluation of an outreach campaign 
to— 
‘‘(i) increase awareness of comprehen-
sive tobacco cessation services covered in 
the State child health plan among— 
‘‘(I) individuals who are likely to 
be eligible for medical assistance 
under the State child health plan; and 
‘‘(II) clinicians and others who 
provide services to individuals who are 
likely to be eligible for medical assist-
ance under the State child health 
plan; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01210
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1211 
‘‘(ii) increase awareness of the bene-
fits of using comprehensive tobacco ces-
sation services covered in the State child 
health plan among— 
‘‘(I) individuals who are likely to 
be eligible for medical assistance 
under the State child health plan; and 
‘‘(II) clinicians and others who 
provide services to individuals who are 
likely to be eligible for medical assist-
ance under the State child health plan 
about the benefits of using com-
prehensive tobacco cessation serv-
ices.’’. 
(2) ADJUSTMENT OF CHIP ALLOTMENTS.—Sec-
tion 2104(m) of the Social Security Act (42 U.S.C. 
1397dd(m)) is amended— 
(A) in paragraph (2)(B), by striking ‘‘and 
(12)’’ and inserting ‘‘(12), and (13)’’; and 
(B) by adding at the end the following new 
paragraph: 
‘‘(13) ADJUSTING
ALLOTMENTS
TO
ACCOUNT 
FOR FEDERAL PAYMENTS FOR CHIP COVERAGE OF 
COMPREHENSIVE
TOBACCO
CESSATION
SERVICES 
AND OUTREACH CAMPAIGN.—If a State (including 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01211
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1212 
the District of Columbia and each commonwealth 
and territory) receives a payment for a fiscal year 
under section 2105(a)(5), the allotment determined 
for the State for such fiscal year shall be increased 
by the amount of such payment.’’. 
(m) NO PRIOR AUTHORIZATION FOR TOBACCO CES-
SATION DRUGS UNDER CHIP.—Section 2103 of the So-
cial Security Act (42 U.S.C. 1397cc), as amended by sub-
section (h), is further amended— 
(1) in subsection (c)(2)(A), by inserting ‘‘(in ac-
cordance with subsection (h))’’ after ‘‘Coverage of 
prescription drugs’’; and 
(2) by adding at the end the following new sub-
section: 
‘‘(h) NO PRIOR AUTHORIZATION PROGRAMS FOR TO-
BACCO CESSATION DRUGS.—A State child health plan 
may not require, as a condition of coverage or payment 
for prescription drugs, the approval of an agent to pro-
mote smoking cessation (including agents approved by the 
Food and Drug Administration) or tobacco cessation.’’. 
(n) COMPREHENSIVE COVERAGE OF TOBACCO CES-
SATION COVERAGE IN PRIVATE HEALTH INSURANCE.— 
Section 2713 of the Public Health Service Act (42 U.S.C. 
300gg–13) is amended by adding at the end the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01212
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1213 
‘‘(d) NO PRIOR AUTHORIZATION.—A group health 
plan and a health insurance issuer offering group or indi-
vidual health insurance coverage shall not impose any 
prior authorization requirement for tobacco cessation 
counseling and pharmacotherapy that has in effect a rat-
ing of ‘A’ or ‘B’ in the current recommendations of the 
United States Preventive Services Task Force.’’. 
(o) RULE OF CONSTRUCTION.—None of the amend-
ments made by this section shall be construed to limit cov-
erage of any counseling or pharmacotherapy for individ-
uals under 18 years of age. 
(p) EFFECTIVE DATE.—The amendments made by 
this section shall take effect on the first day of the first 
fiscal year that begins on or after the date of enactment 
of this Act. 
SEC. 7306. CLINICAL RESEARCH FUNDING FOR ORAL 
HEALTH. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall expand and intensify the conduct 
and support of the research activities of the National In-
stitutes of Health and the National Institute of Dental 
and Craniofacial Research to improve the oral health of 
the population through the prevention and management 
of oral diseases and conditions. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01213
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1214 
(b) INCLUDED RESEARCH ACTIVITIES.—Research 
activities under subsection (a) shall include— 
(1) comparative effectiveness research and clin-
ical disease management research addressing early 
childhood cancer and oral cancer; and 
(2) awarding of grants and contracts to support 
the training and development of health services re-
searchers, comparative effectiveness researchers, and 
clinical researchers whose research improves the oral 
health of the population. 
SEC. 7307. GUIDE ON EVIDENCE-BASED STRATEGIES FOR 
PUBLIC HEALTH DEPARTMENT OBESITY PRE-
VENTION PROGRAMS. 
(a) DEVELOPMENT AND DISSEMINATION OF AN EVI-
DENCE-BASED STRATEGIES GUIDE.—The Secretary of 
Health and Human Services (referred to in this section 
as the ‘‘Secretary’’), acting through the Director of the 
Centers for Disease Control and Prevention, not later than 
2 years after the date of enactment of this Act, shall— 
(1) develop a guide on evidence-based strategies 
for State, territorial, and local health departments to 
use to build and maintain effective obesity preven-
tion and reduction programs, and, in consultation 
with stakeholders that have expertise in Tribal 
health, a guide on such evidence-based strategies 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01214
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1215 
with respect to Indian Tribes and Tribal organiza-
tions for such Indian Tribes and Tribal organiza-
tions to use for such purpose, both of which guides 
shall— 
(A) describe an integrated program struc-
ture for implementing interventions proven to 
be effective in preventing and reducing the inci-
dence of obesity; and 
(B) recommend— 
(i) optimal resources, including staff-
ing and infrastructure, for promoting nu-
trition and obesity prevention and reduc-
tion; and 
(ii) strategies for effective obesity pre-
vention programs for State and local 
health departments, Indian Tribes, and 
Tribal organizations, including strategies 
related to— 
(I) the application of evidence- 
based and evidence-informed practices 
to prevent and reduce obesity rates; 
(II) the development, implemen-
tation, and evaluation of obesity pre-
vention and reduction strategies for 
specific communities and populations; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01215
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1216 
(III) demonstrated knowledge of 
obesity prevention practices that re-
duce associated preventable diseases, 
health conditions, death, and health 
care costs; 
(IV) best practices for the coordi-
nation of efforts to prevent and re-
duce obesity and related chronic dis-
eases; 
(V) addressing the underlying 
risk factors and social determinants of 
health that impact obesity rates; and 
(VI) interdisciplinary coordina-
tion between relevant public health of-
ficials specializing in fields such as 
nutrition, physical activity, epidemi-
ology, communications, and policy im-
plementation, and collaboration be-
tween public health officials and com-
munity-based organizations; and 
(2) disseminate the guides and current re-
search, evidence-based practices, tools, and edu-
cational materials related to obesity prevention, con-
sistent with the guides, to State and local health de-
partments, Indian Tribes, and Tribal organizations. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01216
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1217 
(b) TECHNICAL ASSISTANCE.—The Secretary, acting 
through the Director of the Centers for Disease Control 
and Prevention, shall provide technical assistance to State 
and local health departments, Indian Tribes, and Tribal 
organizations to support such health departments in im-
plementing the guides developed under subsection (a)(1). 
(c) INDIAN TRIBES; TRIBAL ORGANIZATIONS.—In 
this section, the terms ‘‘Indian Tribe’’ and ‘‘Tribal organi-
zation’’ have the meanings given the terms in section 4 
of the Indian Self-Determination and Education Assist-
ance Act (25 U.S.C. 5304). 
SEC. 7308. STEPHANIE TUBBS JONES UTERINE FIBROID RE-
SEARCH AND EDUCATION ACT. 
(a) RESEARCH
WITH
RESPECT
TO
UTERINE 
FIBROIDS.— 
(1) RESEARCH.—The Secretary of Health and 
Human Services (referred to in this section as the 
‘‘Secretary’’) shall expand, intensify, and coordinate 
programs for the conduct and support of research 
with respect to uterine fibroids. 
(2) ADMINISTRATION
AND
COORDINATION.— 
The Secretary shall carry out the conduct and sup-
port of research pursuant to paragraph (1), in co-
ordination with the appropriate institutes, offices, 
and centers of the National Institutes of Health and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01217
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1218 
any other relevant Federal agency, as determined by 
the Director of the National Institutes of Health. 
(3) AUTHORIZATION OF APPROPRIATIONS.—For 
the purpose of carrying out this subsection, there 
are authorized to be appropriated $30,000,000 for 
each of fiscal years 2025 through 2029. 
(b) RESEARCH WITH RESPECT TO MEDICAID COV-
ERAGE OF UTERINE FIBROIDS TREATMENT.— 
(1) RESEARCH.—The Secretary (or the Sec-
retary’s designee) shall establish a research data-
base, or expand an existing research database, to 
collect data on services furnished to individuals diag-
nosed with uterine fibroids under a State plan (or a 
waiver of such a plan) under the Medicaid program 
under title XIX of the Social Security Act (42 
U.S.C. 1396 et seq.) or under a State child health 
plan (or a waiver of such a plan) under the Chil-
dren’s Health Insurance Program under title XXI of 
such Act (42 U.S.C. 1397aa et seq.) for the treat-
ment of such fibroids for purposes of assessing the 
frequency at which such individuals are furnished 
such services. 
(2) REPORT.— 
(A) IN GENERAL.—Not later than 2 years 
after the date of enactment of this Act, the Sec-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01218
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1219 
retary shall submit to Congress a report on the 
amount of Federal and State expenditures with 
respect to services furnished for the treatment 
of uterine fibroids under State plans (or waivers 
of such plans) under the Medicaid program 
under such title XIX and State child health 
plans (or waivers of such plans) under the Chil-
dren’s Health Insurance Program under such 
title XXI. 
(B) COORDINATION.—The Secretary shall 
coordinate the development and submission of 
the report required under paragraph (1) with 
any other relevant Federal agency, as deter-
mined by the Secretary. 
(c) EDUCATION AND DISSEMINATION OF INFORMA-
TION WITH RESPECT TO UTERINE FIBROIDS.— 
(1) UTERINE
FIBROIDS
PUBLIC
EDUCATION 
PROGRAM.—The Secretary shall develop and dis-
seminate to the public information regarding uterine 
fibroids, including information on— 
(A) the awareness, incidence, and preva-
lence of uterine fibroids among individuals, in-
cluding all minority individuals; 
(B) the elevated risk for minority individ-
uals to develop uterine fibroids; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01219
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1220 
(C) the availability, as medically appro-
priate, of the range of treatment options for 
symptomatic uterine fibroids, including non- 
hysterectomy treatments and procedures. 
(2) DISSEMINATION
OF
INFORMATION.—The 
Secretary may disseminate information under para-
graph (1) directly or through arrangements with 
intra-agency initiatives, nonprofit organizations, con-
sumer groups, institutions of higher education (as 
defined in section 101 of the Higher Education Act 
of 1965 (20 U.S.C. 1001)), or Federal, State, or 
local public private partnerships. 
(3) AUTHORIZATION OF APPROPRIATIONS.—For 
the purpose of carrying out this subsection, there 
are authorized to be appropriated such sums as may 
be necessary for each of fiscal years 2025 through 
2029. 
(d) INFORMATION
TO HEALTH CARE PROVIDERS 
WITH RESPECT TO UTERINE FIBROIDS.— 
(1) DISSEMINATION
OF
INFORMATION.—The 
Secretary shall, in consultation and in accordance 
with guidelines from relevant medical societies, work 
with health care-related specialty societies and 
health systems to promote evidence-based care for 
individuals with fibroids. Such efforts shall include 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01220
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1221 
minority individuals who have an elevated risk to de-
velop uterine fibroids and the range of available op-
tions for the treatment of symptomatic uterine 
fibroids, including non-hysterectomy drugs and de-
vices approved under the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 301 et seq.). 
(2) AUTHORIZATION OF APPROPRIATIONS.—For 
the purpose of carrying out this subsection, there 
are authorized to be appropriated such sums as may 
be necessary for each of fiscal years 2025 through 
2029. 
(e) DEFINITION.—In this section, the term ‘‘minority 
individuals’’ means individuals who are members of a ra-
cial and ethnic minority group, as defined in section 
1707(g) of the Public Health Service Act (42 U.S.C. 
300u–6(g)). 
Subtitle E—HIV/AIDS 
SEC. 7401. STATEMENT OF POLICY. 
It is the policy of the United States to achieve an 
AIDS-free generation, and to— 
(1) expand access to lifesaving antiretroviral 
therapy for people living with HIV and immediately 
link people to continuous and coordinated high-qual-
ity care when they learn they are living with HIV; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01221
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1222 
(2) expand targeted efforts to prevent HIV in-
fection using a combination of effective, evidence- 
based approaches, including routine HIV screening, 
and universal access to HIV prevention tools, includ-
ing preexposure prophylaxis, in communities dis-
proportionately impacted by HIV, particularly com-
munities of color; 
(3) ensure laws, policies, and regulations do not 
impede access to prevention, treatment, and care for 
people living with HIV or disproportionately im-
pacted by HIV; 
(4) accelerate research for more efficacious HIV 
prevention and treatments, tools, a cure, and a vac-
cine; and 
(5) respect the human rights and dignity of 
persons living with HIV. 
SEC. 7402. ADDITIONAL FUNDING FOR AIDS DRUG ASSIST-
ANCE PROGRAM TREATMENTS. 
Section 2623 of the Public Health Service Act (42 
U.S.C. 300ff–31b) is amended by adding at the end the 
following: 
‘‘(c) ADDITIONAL FUNDING FOR AIDS DRUG AS-
SISTANCE
PROGRAM
TREATMENTS.—In addition to 
amounts otherwise authorized to be appropriated for car-
rying out this subpart, there are authorized to be appro-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01222
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1223 
priated such sums as may be necessary to carry out sec-
tions 2612(b)(3)(B) and 2616 for each of fiscal years 
2025 through 2028.’’. 
SEC. 7403. ENHANCING THE NATIONAL HIV SURVEILLANCE 
SYSTEM. 
(a) GRANTS.—The Secretary of Health and Human 
Services, acting through the Director of the Centers for 
Disease Control and Prevention, shall make grants to 
States to support integration of public health surveillance 
systems into all electronic health records in order to allow 
rapid communications between the clinical setting and 
health departments, by means that include— 
(1) providing technical assistance and policy 
guidance to State and local health departments, clin-
ical providers, and other agencies serving individuals 
with HIV to improve the interoperability of data sys-
tems relevant to monitoring HIV care and sup-
portive services; 
(2) capturing longitudinal data pertaining to 
the initiation and ongoing prescription or dispensing 
of antiretroviral therapy for individuals diagnosed 
with HIV (such as through pharmacy-based report-
ing); 
(3) obtaining information— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01223
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1224 
(A) on a voluntary basis, on sexual orienta-
tion and gender identity; and 
(B) on sources of coverage (or the lack of 
coverage) for medical treatment (including cov-
erage through the Medicaid program under title 
XIX of the Social Security Act (42 U.S.C. 1396 
et seq.), the Medicare program under title 
XVIII of such Act (42 U.S.C. 1395 et seq.), the 
program under title XXVI of the Public Health 
Service Act (42 U.S.C. 300ff–11 et seq.; com-
monly referred to as the ‘‘Ryan White HIV/ 
AIDS Program’’), other public funding, private 
insurance, and health maintenance organiza-
tions); and 
(4) obtaining and using current geographic 
markers of residence (such as current address, ZIP 
Code, partial ZIP Code, and census block). 
(b) PRIVACY AND SECURITY SAFEGUARDS.—In car-
rying out this section, the Secretary of Health and Human 
Services shall ensure that appropriate privacy and security 
safeguards are met to prevent unauthorized disclosure of 
protected health information and compliance with the 
HIPAA privacy and security law (as defined in section 
3009 of the Public Health Service Act (42 U.S.C. 300jj– 
19)) and other relevant laws and regulations. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01224
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1225 
(c) PROHIBITION
AGAINST
IMPROPER
USE
OF 
DATA.—No grant under this section may be used to allow 
or facilitate the collection or use of surveillance or clinical 
data or records— 
(1) for punitive measures of any kind, civil or 
criminal, against the subject of such data or records; 
or 
(2) for imposing any requirement or restriction 
with respect to an individual without the individual’s 
written consent. 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for each of fiscal years 
2025 through 2028. 
SEC. 7404. EVIDENCE-BASED STRATEGIES FOR IMPROVING 
LINKAGE TO, AND RETENTION IN, APPRO-
PRIATE CARE. 
(a) STRATEGIES.—The Secretary of Health and 
Human Services, in collaboration with the Director of the 
Centers for Disease Control and Prevention, the Assistant 
Secretary for Mental Health and Substance Use, the Di-
rector of the Office of AIDS Research, the Administrator 
of the Health Resources and Services Administration, and 
the Administrator of the Centers for Medicare & Medicaid 
Services, shall— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01225
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1226 
(1) identify evidence-based strategies most ef-
fective at addressing the multifaceted issues that im-
pede disease status awareness with respect to HIV/ 
AIDS and linkage to, and retention in, appropriate 
care, taking into consideration health care systems 
issues, clinic and provider issues, and individual psy-
chosocial, environmental, and other contextual fac-
tors; 
(2) support the wide-scale implementation of 
the evidence-based strategies identified pursuant to 
paragraph (1), including through incorporating such 
strategies into health care coverage supported by the 
Medicaid program under title XIX of the Social Se-
curity Act (42 U.S.C. 1396 et seq.), the program 
under title XXVI of the Public Health Service Act 
(42 U.S.C. 300ff–11 et seq.; commonly referred to 
as the ‘‘Ryan White HIV/AIDS Program’’), and 
health plans purchased through an Exchange estab-
lished under title I of the Patient Protection and Af-
fordable Care Act (Public Law 111–148); and 
(3) not later than 1 year after the date of the 
enactment of this Act, submit a report to the Con-
gress on the status of activities under paragraphs 
(1) and (2). 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01226
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1227 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
SEC. 7405. IMPROVING ENTRY INTO, AND RETENTION IN, 
CARE AND ANTIRETROVIRAL ADHERENCE 
FOR PERSONS WITH HIV. 
(a) SENSE OF CONGRESS.—It is the sense of Con-
gress that AIDS research has led to scientific advance-
ments that have— 
(1) saved the lives of millions of people living 
with HIV; 
(2) prevented millions of individuals from re-
ceiving new diagnoses of HIV; and 
(3) had broad benefits that extend far beyond 
helping people at risk for, or living with, HIV. 
(b) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Director of the Na-
tional Institutes of Health, shall expand, intensify, and co-
ordinate operational and translational research and other 
activities of the National Institutes of Health regarding 
methods— 
(1) to increase adoption of evidence-based ad-
herence strategies within HIV care and treatment 
programs; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01227
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1228 
(2) to increase HIV testing and case detection 
rates; 
(3) to reduce HIV-related health disparities; 
(4) to ensure that research to improve adher-
ence to HIV care and treatment programs address 
the unique concerns of women; 
(5) to integrate HIV prevention and care serv-
ices with mental health and substance use preven-
tion and treatment delivery systems; 
(6) to increase knowledge on the implementa-
tion of preexposure prophylaxis (referred to in this 
section as ‘‘PrEP’’), including with respect to— 
(A) who can benefit most from PrEP; 
(B) how to provide PrEP safely and effi-
ciently; 
(C) how to integrate PrEP with other es-
sential prevention methods such as condoms; 
and 
(D) how to ensure high levels of adherence; 
and 
(7) to increase knowledge of ‘‘undetectable and 
untransmittable’’, when a person living with HIV 
who is on antiretroviral therapy and is durably 
virally suppressed (defined as having a consistent 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01228
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1229 
viral load of less than 200 copies/ml) cannot sexually 
transmit HIV. 
(c) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
SEC. 7406. SERVICES TO REDUCE HIV/AIDS IN RACIAL AND 
ETHNIC MINORITY COMMUNITIES. 
(a) IN GENERAL.—For the purpose of reducing new 
HIV diagnoses in racial and ethnic minority communities, 
the Secretary of Health and Human Services, acting 
through the Deputy Assistant Secretary for Minority 
Health, may make grants to public health agencies and 
faith-based organizations to conduct— 
(1) outreach activities related to HIV preven-
tion and testing activities; 
(2) HIV prevention activities; 
(3) HIV testing activities; and 
(4) public health education campaigns on ac-
cessing HIV prevention medication. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01229
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1230 
SEC. 7407. MINORITY AIDS INITIATIVE. 
(a) EXPANDED FUNDING.—The Secretary of Health 
and Human Services, in collaboration with the Deputy As-
sistant Secretary for Minority Health, the Director of the 
Centers for Disease Control and Prevention, the Adminis-
trator of the Health Resources and Services Administra-
tion, and the Assistant Secretary for Mental Health and 
Substance Use, shall provide funds and carry out activities 
to expand the Minority AIDS Initiative. 
(b) USE OF FUNDS.—The additional funds made 
available under this section may be used, through the Mi-
nority AIDS Initiative, to support the following activities: 
(1) Providing technical assistance and infra-
structure support to reduce HIV/AIDS in minority 
populations. 
(2) Increasing minority populations’ access to 
HIV prevention and care services. 
(3) Building strong community programs and 
partnerships to address HIV prevention and the 
health care needs of specific racial and ethnic minor-
ity populations. 
(c) PRIORITY INTERVENTIONS.—Within the racial 
and ethnic minority populations referred to in subsection 
(b), priority in conducting intervention services shall be 
given to— 
(1) men who have sex with men; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01230
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1231 
(2) youth; 
(3) persons who engage in intravenous drug 
abuse; 
(4) women; 
(5) homeless individuals; 
(6) individuals incarcerated or in the penal sys-
tem; 
(7) transgender individuals; and 
(8) nonbinary individuals. 
(d) AUTHORIZATION OF APPROPRIATIONS.—For car-
rying out this section, there are authorized to be appro-
priated $610,000,000 for fiscal year 2025 and such sums 
as may be necessary for each of fiscal years 2026 through 
2029. 
SEC. 7408. HEALTH CARE PROFESSIONALS TREATING INDI-
VIDUALS WITH HIV. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Administrator of the 
Health Resources and Services Administration, shall ex-
pand, intensify, and coordinate workforce initiatives of the 
Health Resources and Services Administration to increase 
the capacity of the health workforce focusing primarily on 
HIV to meet the demand for culturally competent care, 
and may award grants for any of the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01231
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1232 
(1) Development of curricula for training pri-
mary care providers in HIV/AIDS prevention and 
care, including routine HIV testing. 
(2) Support to expand access to culturally and 
linguistically accessible benefits counselors, trained 
peer navigators, and mental and behavioral health 
professionals with expertise in HIV. 
(3) Training health care professionals to pro-
vide care to individuals living with HIV. 
(4) Development by grant recipients under title 
XXVI of the Public Health Service Act (42 U.S.C. 
300ff–11 et seq.; commonly referred to as the ‘‘Ryan 
White HIV/AIDS Program’’) and other persons, of 
policies for providing culturally relevant and sen-
sitive treatment to individuals living with HIV, with 
particular emphasis on treatment to racial and eth-
nic minorities, men who have sex with men, and 
women, young people, and children living with HIV. 
(5) Development and implementation of pro-
grams to increase the use of telehealth to respond to 
HIV-specific health care needs in rural and minority 
communities, with particular emphasis given to 
medically underserved communities and insular 
areas. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01232
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1233 
(6) Evaluating interdisciplinary medical pro-
vider care team models that promote high-quality 
care, with particular emphasis on care to racial and 
ethnic minorities. 
(7) Training health care professionals to make 
them aware of the high rates of chronic hepatitis B 
and chronic hepatitis C in adult racial and ethnic 
minority populations, and the importance of preven-
tion, detection, and medical management of hepatitis 
B and hepatitis C and of liver cancer screening. 
(8) Development of curricula for training pri-
mary care providers that HIV and tuberculosis are 
significant mutual comorbidities, and that a patient 
who tests positive for one disease should be offered 
and encouraged to receive testing for the other. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
SEC. 7409. HIV/AIDS PROVIDER LOAN REPAYMENT PRO-
GRAM. 
(a) IN GENERAL.—The Secretary may enter into an 
agreement with any physician, nurse practitioner, or phy-
sician assistant under which— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01233
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1234 
(1) the physician, nurse practitioner, or physi-
cian assistant agrees to serve as a medical provider 
for a period of not less than 2 years— 
(A) at a Ryan White-funded or title X- 
funded facility with a critical shortage of doc-
tors (as determined by the Secretary); or 
(B) in an area with a high incidence of 
HIV/AIDS; and 
(2) the Secretary agrees to make payments in 
accordance with subsection (b) on the professional 
education loans of the physician, nurse practitioner, 
or physician assistant. 
(b) MANNER
OF PAYMENTS.—The payments de-
scribed in subsection (a) shall be made by the Secretary 
as follows: 
(1) Upon completion by the physician, nurse 
practitioner, or physician assistant for whom the 
payments are to be made of the first year of the 
service specified in the agreement entered into with 
the Secretary under subsection (a), the Secretary 
shall pay 30 percent of the principal of and the in-
terest on the individual’s professional education 
loans. 
(2) Upon completion by the physician, nurse 
practitioner, or physician assistant of the second 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01234
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1235 
year of such service, the Secretary shall pay another 
30 percent of the principal of and the interest on 
such loans. 
(3) Upon completion by that individual of a 
third year of such service, the Secretary shall pay 
another 25 percent of the principal of and the inter-
est on such loans. 
(c) APPLICABILITY OF CERTAIN PROVISIONS.—Sub-
part III of part D of title III of the Public Health Service 
Act (42 U.S.C. 254l et seq.) shall, except as inconsistent 
with this section, apply to the program carried out under 
this section in the same manner and to the same extent 
as such provisions apply to the National Health Service 
Corps loan repayment program. 
(d) REPORTS.—Not later than 18 months after the 
date of the enactment of this Act, and annually thereafter, 
the Secretary shall prepare and submit to Congress a re-
port describing the program carried out under this section, 
including statements regarding the following: 
(1) The number of physicians, nurse practi-
tioners, and physician assistants enrolled in the pro-
gram. 
(2) The number and amount of loan repay-
ments provided through the program. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01235
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1236 
(3) The placement location of loan repayment 
recipients at facilities described in subsection (a)(1). 
(4) The default rate on such loans and actions 
required. 
(5) The amount of outstanding default funds 
with respect to such loans. 
(6) To the extent that it can be determined, the 
reason for the default on such a loan. 
(7) The demographics of individuals partici-
pating in the program. 
(8) An evaluation of the overall costs and bene-
fits of the program. 
(e) DEFINITIONS.—In this section: 
(1) HIV/AIDS.—The term ‘‘HIV/AIDS’’ means 
human immunodeficiency virus and acquired im-
mune deficiency syndrome. 
(2) NURSE PRACTITIONER.—The term ‘‘nurse 
practitioner’’ means a registered nurse who has com-
pleted an accredited graduate degree program in ad-
vanced nurse practice and has successfully passed a 
national certification exam. 
(3) PHYSICIAN.—The term ‘‘physician’’ means 
a graduate of a school of medicine who has com-
pleted postgraduate training in general or pediatric 
medicine. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01236
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1237 
(4) PHYSICIAN ASSISTANT.—The term ‘‘physi-
cian assistant’’ means a medical provider who com-
pleted an accredited physician assistant training pro-
gram and successfully passed the Physician Assist-
ant National Certifying Examination. 
(5) PROFESSIONAL
EDUCATION
LOAN.—The 
term ‘‘professional education loan’’— 
(A) means a loan that is incurred for the 
cost of attendance (including tuition, other rea-
sonable educational expenses, and reasonable 
living costs) at a school of medicine, school of 
nursing, or physician assistant training pro-
gram; and 
(B) includes only the portion of the loan 
that is outstanding on the date the physician, 
nurse practitioner, or physician assistant in-
volved begins the service specified in the agree-
ment under subsection (a). 
(6) RYAN WHITE-FUNDED.—The term ‘‘Ryan 
White-funded’’ means, with respect to a facility, re-
ceiving funds under title XXVI of the Public Health 
Service Act (42 U.S.C. 300ff–11 et seq.). 
(7) SECRETARY.—The term ‘‘Secretary’’ means 
the Secretary of Health and Human Services. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01237
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1238 
(8) SCHOOL OF MEDICINE.—The term ‘‘school 
of medicine’’ has the meaning given to that term in 
section 799B of the Public Health Service Act (42 
U.S.C. 295p). 
(9) TITLE X-FUNDED.—The term ‘‘title X-fund-
ed’’ means, with respect to a facility, receiving funds 
under title X of the Public Health Service Act (42 
U.S.C. 300 et seq.). 
(f) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
SEC. 7410. DENTAL EDUCATION LOAN REPAYMENT PRO-
GRAM. 
(a) IN GENERAL.—The Secretary may enter into an 
agreement with any dentist under which— 
(1) the dentist agrees to serve as a dentist for 
a period of not less than 2 years at a facility with 
a critical shortage of dentists (as determined by the 
Secretary) in an area with a high incidence of HIV/ 
AIDS; and 
(2) the Secretary agrees to make payments in 
accordance with subsection (b) on the dental edu-
cation loans of the dentist. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01238
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1239 
(b) MANNER
OF PAYMENTS.—The payments de-
scribed in subsection (a) shall be made by the Secretary 
as follows: 
(1) Upon completion by the dentist for whom 
the payments are to be made of the first year of the 
service specified in the agreement entered into with 
the Secretary under subsection (a), the Secretary 
shall pay 30 percent of the principal of and the in-
terest on the dental education loans of the dentist. 
(2) Upon completion by the dentist of the sec-
ond year of such service, the Secretary shall pay an-
other 30 percent of the principal of and the interest 
on such loans. 
(3) Upon completion by that individual of a 
third year of such service, the Secretary shall pay 
another 25 percent of the principal of and the inter-
est on such loans. 
(c) APPLICABILITY OF CERTAIN PROVISIONS.—Sub-
part III of part D of title III of the Public Health Service 
Act (42 U.S.C. 254l et seq.) shall, except as inconsistent 
with this section, apply to the program carried out under 
this section in the same manner and to the same extent 
as such provisions apply to the National Health Service 
Corps Loan Repayment Program. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01239
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1240 
(d) REPORTS.—Not later than 18 months after the 
date of the enactment of this Act, and annually thereafter, 
the Secretary shall prepare and submit to the Congress 
a report describing the program carried out under this sec-
tion, including statements regarding the following: 
(1) The number of dentists enrolled in the pro-
gram. 
(2) The number and amount of loan repay-
ments provided through the program. 
(3) The placement location of loan repayment 
recipients at facilities described in subsection (a)(1). 
(4) The default rate on such loans and actions 
required. 
(5) The amount of outstanding default funds 
with respect to such loans. 
(6) To the extent that it can be determined, the 
reason for the default on such a loan. 
(7) The demographics of individuals partici-
pating in the program. 
(8) An evaluation of the overall costs and bene-
fits of the program. 
(e) DEFINITIONS.—In this section: 
(1) DENTAL
EDUCATION
LOAN.—The term 
‘‘dental education loan’’— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01240
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1241 
(A) means a loan that is incurred for the 
cost of attendance (including tuition, other rea-
sonable educational expenses, and reasonable 
living costs) at a school of dentistry; and 
(B) includes only the portion of the loan 
that is outstanding on the date the dentist in-
volved begins the service specified in the agree-
ment under subsection (a). 
(2) DENTIST.—The term ‘‘dentist’’ means a 
graduate of a school of dentistry who has completed 
postgraduate training in general or pediatric den-
tistry. 
(3) HIV/AIDS.—The term ‘‘HIV/AIDS’’ means 
human immunodeficiency virus and acquired im-
mune deficiency syndrome. 
(4) SCHOOL OF DENTISTRY.—The term ‘‘school 
of dentistry’’ has the meaning given to that term in 
section 799B of the Public Health Service Act (42 
U.S.C. 295p). 
(5) SECRETARY.—The term ‘‘Secretary’’ means 
the Secretary of Health and Human Services. 
(f) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for each of fiscal years 
2025 through 2028. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01241
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1242 
SEC. 7411. REDUCING NEW HIV INFECTIONS AMONG IN-
JECTING DRUG USERS. 
(a) SENSE OF CONGRESS.—It is the sense of Con-
gress that providing sterile syringes and sterilized equip-
ment to injecting drug users substantially reduces risk of 
HIV infection, increases the probability that they will ini-
tiate drug treatment, and does not increase drug use. 
(b) IN GENERAL.—The Secretary of Health and 
Human Services may provide grants and technical assist-
ance for the purpose of reducing the rate of HIV infections 
among injecting drug users through a comprehensive 
package of services for such users, including the provision 
of sterile syringes, education and outreach, access to infec-
tious disease testing, overdose prevention, and treatment 
for drug dependence. 
(c) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2025 
through 2028. 
SEC. 7412. REPORT ON IMPACT OF HIV/AIDS IN VULNER-
ABLE POPULATIONS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall submit to Congress and the Presi-
dent an annual report on the impact of HIV/AIDS for 
racial and ethnic minority communities, women, and youth 
aged 24 and younger. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01242
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1243 
(b) CONTENTS.—The report under subsection (a) 
shall include information on the— 
(1) progress that has been made in reducing 
the impact of HIV/AIDS in such communities; 
(2) opportunities that exist to make additional 
progress in reducing the impact of HIV/AIDS in 
such communities; 
(3) challenges that may impede such additional 
progress; and 
(4) Federal funding necessary to achieve sub-
stantial reductions in HIV/AIDS in racial and ethnic 
minority communities. 
SEC. 7413. NATIONAL HIV/AIDS OBSERVANCE DAYS. 
(a) NATIONAL OBSERVANCE DAYS.—It is the sense 
of Congress that national observance days highlighting the 
impact of HIV on communities of color include the fol-
lowing: 
(1) National Black HIV/AIDS Awareness Day. 
(2) National Latino AIDS Awareness Day. 
(3) National Asian and Pacific Islander HIV/ 
AIDS Awareness Day. 
(4) National Native American HIV/AIDS 
Awareness Day. 
(5) National Youth HIV/AIDS Awareness Day. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01243
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1244 
(b) CALL TO ACTION.—It is the sense of Congress 
that the President should call on members of communities 
of color— 
(1) to become involved at the local community 
level in HIV testing, policy, and advocacy; 
(2) to become aware, engaged, and empowered 
on the HIV epidemic within their communities; and 
(3) to urge members of their communities to re-
duce risk factors, practice safe sex and other preven-
tive measures, be tested for HIV, and seek care 
when appropriate. 
SEC. 7414. REVIEW OF ALL FEDERAL AND STATE LAWS, 
POLICIES, AND REGULATIONS REGARDING 
THE CRIMINAL PROSECUTION OF INDIVID-
UALS FOR HIV-RELATED OFFENSES. 
(a) SENSE OF CONGRESS REGARDING LAWS OR REG-
ULATIONS DIRECTED AT PEOPLE LIVING WITH HIV.— 
It is the sense of Congress that Federal and State laws, 
policies, and regulations regarding people living with 
HIV— 
(1) should not place unique or additional bur-
dens on such individuals solely as a result of their 
HIV status; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01244
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1245 
(2) should instead demonstrate a public health- 
oriented, evidence-based, medically accurate, and 
contemporary understanding of— 
(A) the multiple factors that lead to HIV 
transmission; 
(B) the relative risk of demonstrated HIV 
transmission routes; 
(C) the current health implications of liv-
ing with HIV; 
(D) the associated benefits of treatment 
and support services for people living with HIV; 
and 
(E) the impact of punitive HIV-specific 
laws, policies, regulations, and judicial prece-
dents and decisions on public health, on people 
living with or affected by HIV, and on their 
families and communities. 
(b) REVIEW OF FEDERAL AND STATE LAWS.— 
(1) REVIEW OF FEDERAL AND STATE LAWS.— 
(A) IN GENERAL.—Not later than 90 days 
after the date of the enactment of this Act, the 
Attorney General, the Secretary of Health and 
Human Services, and the Secretary of Defense 
acting jointly (in this section referred to as the 
‘‘designated officials’’) shall initiate a national 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01245
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1246 
review of Federal and State laws, including the 
Uniform Code of Military Justice (referred to in 
this section as the ‘‘UCMJ’’), policies, regula-
tions, and judicial precedents and decisions re-
garding criminal and related civil commitment 
cases involving people living with HIV/AIDS. 
(B) CONSULTATION.—In carrying out the 
review under subparagraph (A), the designated 
officials shall seek to include diverse participa-
tion from, and consultation with, each of the 
following: 
(i) Each State. 
(ii) State attorneys general (or their 
representatives). 
(iii) State public health officials (or 
their representatives). 
(iv) State judicial and court system 
officers, including judges, district attor-
neys, prosecutors, defense attorneys, law 
enforcement, and correctional officers. 
(v) Members of the United States 
Armed Forces, including members of other 
Federal services subject to the UCMJ. 
(vi) People living with HIV/AIDS, 
particularly those who have been subject to 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01246
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1247 
HIV-related prosecution or who are from 
minority communities whose members have 
been disproportionately subject to HIV- 
specific arrests and prosecution. 
(vii) Legal advocacy and HIV/AIDS 
service organizations that work with people 
living with HIV/AIDS. 
(viii) Nongovernmental health organi-
zations that work on behalf of people living 
with HIV/AIDS, including syringe services 
programs, LGBTQ-focused health organi-
zations, and organizations who serve peo-
ple who engage in sex work. 
(ix) Trade organizations or associa-
tions representing persons or entities de-
scribed in clauses (i) through (vii). 
(C) RELATION
TO
OTHER
REVIEWS.—In 
carrying out the review under subparagraph 
(A), the designated officials may utilize other 
existing reviews of criminal and related civil 
commitment cases involving people living with 
HIV, including any such review conducted by 
any Federal or State agency or any public 
health, legal advocacy, or trade organization or 
association if the designated officials determines 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01247
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1248 
that such reviews were conducted in accordance 
with the principles set forth in subsection (a). 
(2) REPORT.—Not later than 180 days after 
initiating the review required under paragraph (1), 
the Attorney General shall transmit to the Congress 
and make publicly available a report containing the 
results of the review, which includes the following: 
(A) For each State and for the UCMJ, a 
summary of the relevant laws, policies, regula-
tions, and judicial precedents and decisions re-
garding criminal cases involving people living 
with HIV, including the following: 
(i) A determination of whether such 
laws, policies, regulations, and judicial 
precedents and decisions place any unique 
or additional burdens upon people living 
with HIV. 
(ii) A determination of whether such 
laws, policies, regulations, and judicial 
precedents and decisions demonstrate a 
public 
health-oriented, 
evidence-based, 
medically accurate, and contemporary un-
derstanding of— 
(I) the multiple factors that lead 
to HIV transmission; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01248
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1249 
(II) the relative risk of HIV 
transmission routes, including that a 
person that has an undetectable viral 
load cannot transmit HIV; 
(III) the current health implica-
tions of living with HIV, including 
data disaggregated by race and eth-
nicity; 
(IV) the current status of pro-
viding protection to people who en-
gage in survival sex work against 
whom condom possession has been 
used as evidence of intent to commit 
a crime; 
(V) States that have the classi-
fication of mandatory sex offenders; 
(VI) the associated benefits of 
treatment and support services for 
people living with HIV; and 
(VII) the impact of punitive 
HIV-specific laws and policies on pub-
lic health, on people living with or af-
fected by HIV, and on their families 
and communities, including people 
who are in abusive, dependent, violent, 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01249
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1250 
or nonconsensual relationships and 
are unable to both negotiate the use 
of condoms and status disclosure. 
(iii) An analysis of the public health 
and legal implications of such laws, poli-
cies, regulations, and judicial precedents 
and decisions, including an analysis of the 
consequences of having a similar penal 
scheme applied to comparable situations 
involving other communicable diseases. 
(iv) An analysis of the proportionality 
of punishments imposed under HIV-spe-
cific laws, policies, regulations, and judicial 
precedents, taking into consideration pen-
alties attached to violation of State laws 
against similar degrees of endangerment or 
harm, such as driving while intoxicated or 
transmission of other communicable dis-
eases, or more serious harms, such as ve-
hicular manslaughter offenses. 
(B) An analysis of common elements 
shared between State laws, policies, regulations, 
and judicial precedents. 
(C) A set of best practice recommendations 
directed to State governments, including State 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01250
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1251 
attorneys general, public health officials, and 
judicial officers, in order to ensure that laws, 
policies, regulations, and judicial precedents re-
garding people living with HIV are in accord-
ance with the principles set forth in subsection 
(a). 
(D) Recommendations for adjustments to 
the UCMJ, including discontinuing the use of a 
service member’s HIV diagnosis as the basis for 
prosecution, enhanced penalties, or discharge 
from military service, in order to ensure that 
laws, policies, regulations, and judicial prece-
dents regarding people living with HIV are in 
accordance with the principles set forth in sub-
section (a). Such recommendations should in-
clude any necessary and appropriate changes to 
‘‘Orders to Follow Preventative Medicine Re-
quirements’’. 
(3) GUIDANCE.—Not later than 90 days after 
the date of the release of the report required by 
paragraph (2), the Attorney General and the Sec-
retary of Health and Human Services shall jointly 
develop and publicly release updated guidance for 
States based on the set of best practice rec-
ommendations required under paragraph (2)(C) in 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01251
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1252 
order to assist States dealing with criminal and re-
lated civil commitment cases regarding people living 
with HIV. 
(4) MONITORING AND EVALUATION SYSTEM.— 
Not later than 60 days after the date of the release 
of the guidance required under paragraph (3), the 
Attorney General and the Secretary of Health and 
Human Services shall jointly establish an integrated 
monitoring and evaluation system that includes, 
where appropriate, objective and quantifiable per-
formance goals and indicators to measure progress 
toward statewide implementation in each State of 
the best practice recommendations required under 
paragraph (2)(C). 
(5) MODERNIZATION OF FEDERAL LAWS, POLI-
CIES, AND REGULATIONS.—Not later than 90 days 
after the date of the release of the report required 
under paragraph (2), the designated officials shall 
develop and transmit to the President and the Con-
gress, and make publicly available, such proposals as 
may be necessary to implement adjustments to Fed-
eral laws, policies, or regulations, including the 
UCMJ, based on the recommendations required 
under paragraph (2)(D), either through Executive 
order or through changes to statutory law. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01252
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1253 
(c) RULE OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed to discourage the prosecution of 
individuals who intentionally transmit or attempt to trans-
mit HIV to another individual. 
(d) NO
ADDITIONAL
APPROPRIATIONS
AUTHOR-
IZED.—This section shall not be construed to increase the 
amount of appropriations that are authorized to be appro-
priated for any fiscal year. 
SEC. 7415. EXPANDING SUPPORT FOR CONDOMS IN PRIS-
ONS. 
(a) SENSE OF CONGRESS REGARDING DISTRIBUTION 
OF SEXUAL BARRIER PROTECTION DEVICES IN STATE 
PRISON SYSTEMS.—It is the sense of the Congress that 
States shall allow for the legal distribution of sexual bar-
rier protection devices in State correctional facilities to re-
duce the prevalence and spread of STIs in those facilities. 
(b) AUTHORITY TO ALLOW COMMUNITY ORGANIZA-
TIONS TO PROVIDE STI COUNSELING, STI PREVENTION 
EDUCATION, AND SEXUAL BARRIER PROTECTION DE-
VICES IN FEDERAL CORRECTIONAL FACILITIES.— 
(1) DIRECTIVE TO ATTORNEY GENERAL.—Not 
later than 30 days after the date of enactment of 
this Act, the Attorney General shall direct the Direc-
tor of the Bureau of Prisons to allow community or-
ganizations to, in accordance with all relevant Fed-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01253
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1254 
eral laws and regulations that govern visitation in 
Federal correctional facilities— 
(A) distribute sexual barrier protection de-
vices in Federal correctional facilities; and 
(B) engage in STI counseling and STI pre-
vention education in Federal correctional facili-
ties. 
(2) INFORMATION
REQUIREMENT.—Any com-
munity organization permitted to distribute sexual 
barrier protection devices under paragraph (1) shall 
ensure that the individuals to whom the devices are 
distributed are informed about the proper use and 
disposal of sexual barrier protection devices in ac-
cordance with established public health practices. 
Any community organization conducting STI coun-
seling or STI prevention education under paragraph 
(1) shall offer comprehensive sexuality education. 
(3) POSSESSION
OF
DEVICE
PROTECTED.—A 
Federal correctional facility may not, because of the 
possession or use of a sexual barrier protection de-
vice— 
(A) take adverse action against an incar-
cerated individual; or 
(B) consider possession or use as evidence 
of prohibited activity for the purpose of any 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01254
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1255 
Federal correctional facility administrative pro-
ceeding. 
(4) IMPLEMENTATION.—The Attorney General 
and the Director of the Bureau of Prisons shall im-
plement this section according to established public 
health practices in a manner that protects the 
health, safety, and privacy of incarcerated individ-
uals and of correctional facility staff. 
(c) SURVEY OF AND REPORT ON CORRECTIONAL FA-
CILITY PROGRAMS AIMED AT REDUCING THE SPREAD OF 
STIS.— 
(1) SURVEY.—Not later than 180 days after 
the date of enactment of this Act, and annually 
thereafter for 5 years, the Attorney General, after 
consulting with the Secretary of Health and Human 
Services, State officials, and community organiza-
tions, shall, to the maximum extent practicable, con-
duct a survey of all Federal and State correctional 
facilities, to determine the following: 
(A) COUNSELING, TREATMENT, AND SUP-
PORTIVE SERVICES.—Whether the correctional 
facility— 
(i) requires incarcerated individuals to 
participate in counseling, treatment, and 
supportive services related to STIs; or 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01255
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1256 
(ii) offers such programs to incarcer-
ated individuals. 
(B) ACCESS TO SEXUAL BARRIER PROTEC-
TION DEVICES.—Whether incarcerated individ-
uals can— 
(i) possess sexual barrier protection 
devices; 
(ii) purchase sexual barrier protection 
devices; 
(iii) purchase sexual barrier protection 
devices at a reduced cost; or 
(iv) obtain sexual barrier protection 
devices without cost. 
(C) INCIDENCE OF SEXUAL VIOLENCE.— 
The incidence of sexual violence and assault 
committed by incarcerated individuals and by 
correctional facility staff. 
(D) PREVENTION EDUCATION OFFERED.— 
The type of prevention education, information, 
or training offered to incarcerated individuals 
and correctional facility staff regarding sexual 
violence and the spread of STIs, including 
whether such education, information, or train-
ing— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01256
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1257 
(i) constitutes comprehensive sexuality 
education; 
(ii) is compulsory for new incarcerated 
individuals and for new correctional facility 
staff; and 
(iii) is offered on an ongoing basis. 
(E) STI TESTING.—Whether the correc-
tional facility tests incarcerated individuals for 
STIs or gives them the option to undergo such 
testing— 
(i) at intake; 
(ii) on a regular basis; and 
(iii) prior to release. 
(F) STI TEST RESULTS.—The number of 
incarcerated individuals who are tested for STIs 
and the outcome of such tests at each correc-
tional facility, disaggregated to include results 
for— 
(i) the type of STI tested for; 
(ii) the race and ethnicity of an indi-
vidual tested; 
(iii) the age of an individual tested; 
and 
(iv) the gender of the individual test-
ed. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01257
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1258 
(G) PRERELEASE
REFERRAL
POLICY.— 
Whether incarcerated individuals are informed 
prior to release about STI-related services or 
other health services in their communities, in-
cluding free and low-cost counseling and treat-
ment options. 
(H) PRERELEASE
REFERRALS
MADE.— 
The number of referrals to community-based 
organizations or public health facilities offering 
STI-related or other health services provided to 
incarcerated individuals prior to release, and 
the type of counseling or treatment for which 
the referral was made. 
(I) REINSTATEMENT OF MEDICAID BENE-
FITS.—Whether— 
(i) the correctional facility assists in-
carcerated individuals that were enrolled in 
the State Medicaid program prior to their 
incarceration in reinstating their enroll-
ment upon release; and 
(ii) such individuals receive referrals 
as described in subparagraph (G) to enti-
ties that accept the State Medicaid pro-
gram, including, if applicable— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01258
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1259 
(I) the number of such individ-
uals, including those diagnosed with 
HIV, that have been reinstated; 
(II) a list of obstacles to rein-
stating enrollment or to making deter-
minations of eligibility for reinstate-
ment, if any; and 
(III) the number of individuals 
denied enrollment. 
(J) OTHER ACTIONS TAKEN.—Whether the 
correctional facility has taken any other action, 
in conjunction with community organizations or 
otherwise, to reduce the prevalence and spread 
of STIs in that facility. 
(2) PRIVACY.—In conducting the survey under 
paragraph (1), the Attorney General shall not re-
quest or retain the identity of any individual who 
has sought or been offered counseling, treatment, 
testing, or prevention education information regard-
ing an STI (including information about sexual bar-
rier protection devices), or who has tested positive 
for an STI. 
(3) REPORT.— 
(A) IN GENERAL.—The Attorney General 
shall transmit to Congress and make publicly 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01259
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1260 
available the results of the survey required 
under paragraph (1), both for the United 
States as a whole and disaggregated as to each 
State and each correctional facility. 
(B) DEADLINES.—To the maximum extent 
possible, the Attorney General shall— 
(i) issue the first report under sub-
paragraph (A) not later than 1 year after 
the date of enactment of this Act; and 
(ii) issue reports under subparagraph 
(A) annually thereafter for 5 years. 
(d) STRATEGY.— 
(1) DIRECTIVE TO ATTORNEY GENERAL.—The 
Attorney General, in consultation with the Secretary 
of Health and Human Services, State officials, and 
community organizations, shall develop and imple-
ment a 5-year strategy to reduce the prevalence and 
spread of STIs in Federal and State correctional fa-
cilities. To the maximum extent possible, the strat-
egy shall be developed, transmitted to Congress, and 
made publicly available not later than 180 days after 
the transmission of the first report required under 
subsection (c)(3). 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01260
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1261 
(2) CONTENTS
OF
STRATEGY.—The strategy 
developed under paragraph (1) shall include the fol-
lowing: 
(A) PREVENTION EDUCATION.—A plan for 
improving prevention education, information, 
and training offered to incarcerated individuals 
and correctional facility staff, including infor-
mation and training on sexual violence and the 
spread of STIs, and comprehensive sexuality 
education. 
(B) SEXUAL BARRIER PROTECTION DEVICE 
ACCESS.—A plan for expanding access to sexual 
barrier protection devices in correctional facili-
ties. 
(C) SEXUAL
VIOLENCE
REDUCTION.—A 
plan for reducing the incidence of sexual vio-
lence among incarcerated individuals and cor-
rectional facility staff. 
(D) COUNSELING AND SUPPORTIVE SERV-
ICES.—A plan for expanding access to coun-
seling and supportive services related to STIs in 
correctional facilities. 
(E) TESTING.—A plan for testing incarcer-
ated individuals for STIs during intake, during 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01261
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1262 
regular health exams, and prior to release 
that— 
(i) is conducted in accordance with 
guidelines established by the Centers for 
Disease Control and Prevention; 
(ii) includes pretest counseling; 
(iii) requires that incarcerated individ-
uals are notified of their option to decline 
testing at any time; 
(iv) requires that incarcerated individ-
uals are confidentially notified of their test 
results in a timely manner; and 
(v) ensures that incarcerated individ-
uals testing positive for STIs receive post- 
test counseling, care, treatment, and sup-
portive services. 
(F) TREATMENT.—A plan for ensuring 
that correctional facilities have the necessary 
medicine and equipment to treat and monitor 
STIs and for ensuring that incarcerated indi-
viduals living with or testing positive for STIs 
receive and have access to care and treatment 
services. 
(G) 
STRATEGIES
FOR
DEMOGRAPHIC 
GROUPS.—A plan for developing and imple-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01262
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1263 
menting culturally appropriate, sensitive, and 
specific strategies to reduce the spread of STIs 
among demographic groups heavily impacted by 
STIs. 
(H) LINKAGES
WITH
COMMUNITIES
AND 
FACILITIES.—A plan for establishing and 
strengthening linkages to local community and 
health facilities that— 
(i) provide counseling, testing, care, 
and treatment services; 
(ii) may receive individuals recently 
released from incarceration who are living 
with STIs; and 
(iii) accept payment through the State 
Medicaid program. 
(I) ENROLLMENT
IN
STATE
MEDICAID 
PROGRAMS.—Plans to ensure that— 
(i) incarcerated individuals who were 
enrolled in their State Medicaid program 
prior to incarceration in a correctional fa-
cility are automatically reenrolled in such 
program upon their release; and 
(ii) incarcerated individuals who were 
not enrolled in their State Medicaid pro-
gram prior to incarceration, and who are 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01263
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1264 
diagnosed with HIV while incarcerated in 
a correctional facility, are automatically 
enrolled in such program upon their re-
lease. 
(J) OTHER PLANS.—Any other plans de-
veloped by the Attorney General for reducing 
the spread of STIs or improving the quality of 
health care in correctional facilities. 
(K) MONITORING SYSTEM.—A monitoring 
system that establishes performance goals re-
lated to reducing the prevalence and spread of 
STIs in correctional facilities and which, where 
feasible, expresses such goals in quantifiable 
form. 
(L) MONITORING
SYSTEM
PERFORMANCE 
INDICATORS.—Performance 
indicators 
that 
measure or assess the achievement of the per-
formance goals described in subparagraph (K). 
(M) COST ESTIMATE.—A detailed estimate 
of the funding necessary to implement the 
strategy at the Federal and State levels for all 
5 years, including the amount of funds required 
by community organizations to implement the 
parts of the strategy in which they take part. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01264
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1265 
(3) REPORT.—Not later than 1 year after the 
date of the enactment of this Act, and annually 
thereafter, the Attorney General shall transmit to 
Congress and make publicly available an annual 
progress report regarding the implementation and 
effectiveness of the strategy described in paragraph 
(1). The progress report shall include an evaluation 
of the implementation of the strategy using the mon-
itoring system and performance indicators provided 
for in subparagraphs (K) and (L) of paragraph (2). 
(e) AUTHORIZATION OF APPROPRIATIONS.— 
(1) IN GENERAL.—There are authorized to be 
appropriated such sums as may be necessary to 
carry out this section for each of fiscal years 2025 
through 2029. 
(2) AVAILABILITY OF FUNDS.—Amounts made 
available under paragraph (1) are authorized to re-
main available until expended. 
(f) DEFINITIONS.—In this section: 
(1) COMMUNITY
ORGANIZATION.—The term 
‘‘community organization’’ means a public health 
care facility or a nonprofit organization that pro-
vides health- or STI-related services according to es-
tablished public health standards. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01265
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1266 
(2) COMPREHENSIVE SEXUALITY EDUCATION.— 
The term ‘‘comprehensive sexuality education’’ 
means sexuality education— 
(A) that includes information about absti-
nence and about the proper use and disposal of 
sexual barrier protection devices; and 
(B) that is— 
(i) evidence based; 
(ii) medically accurate; 
(iii) age and developmentally appro-
priate; 
(iv) gender and identity sensitive; 
(v) culturally and linguistically appro-
priate; and 
(vi) structured to promote critical 
thinking, self-esteem, respect for others, 
and the development of healthy attitudes 
and relationships. 
(3) CORRECTIONAL FACILITY.—The term ‘‘cor-
rectional facility’’ means any prison, penitentiary, 
adult detention facility, juvenile detention facility, 
jail, or other facility to which individuals may be 
sent after conviction of a crime or act of juvenile de-
linquency within the United States. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01266
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1267 
(4) INCARCERATED
INDIVIDUAL.—The term 
‘‘incarcerated individual’’ means any individual who 
is serving a sentence in a correctional facility after 
conviction of a crime. 
(5) SEXUAL BARRIER PROTECTION DEVICE.— 
The term ‘‘sexual barrier protection device’’ means 
any physical device approved, cleared, or otherwise 
authorized by the Food and Drug Administration 
that has not been tampered with and which reduces 
the probability of STI transmission or infection be-
tween sexual partners, including female condoms, 
male condoms, and dental dams. 
(6) SEXUALLY TRANSMITTED INFECTION.—The 
term ‘‘sexually transmitted infection’’ or ‘‘STI’’ 
means any disease or infection that is commonly 
transmitted through sexual activity, including HIV, 
gonorrhea, chlamydia, syphilis, genital herpes, viral 
hepatitis, and human papillomavirus. 
(7) STATE.—The term ‘‘State’’ includes the 
District of Columbia, American Samoa, the Com-
monwealth of the Northern Mariana Islands, Guam, 
Puerto Rico, and the United States Virgin Islands. 
(8) STATE
MEDICAID
PROGRAM.—The term 
‘‘State Medicaid program’’ means the State plan (or 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01267
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1268 
a waiver of such plan) under title XIX of the Social 
Security Act (42 U.S.C. 1396 et seq.). 
SEC. 7416. AUTOMATIC REINSTATEMENT OR ENROLLMENT 
IN MEDICAID FOR PEOPLE WHO TEST POSI-
TIVE FOR HIV BEFORE REENTERING COMMU-
NITIES. 
(a) IN GENERAL.—Section 1902(e) of the Social Se-
curity Act (42 U.S.C. 1396a(e)) is amended by adding at 
the end the following: 
‘‘(17) ENROLLMENT OF EX-OFFENDERS.— 
‘‘(A) AUTOMATIC ENROLLMENT OR REIN-
STATEMENT.— 
‘‘(i) IN
GENERAL.—The State plan 
shall provide for the automatic enrollment 
or reinstatement of enrollment of an eligi-
ble individual— 
‘‘(I) if such individual is sched-
uled to be released from a public insti-
tution due to the completion of sen-
tence, not less than 30 days prior to 
the scheduled date of the release; and 
‘‘(II) if such individual is to be 
released from a public institution on 
parole or on probation, as soon as 
possible after the date on which the 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01268
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1269 
determination to release such indi-
vidual was made, and before the date 
such individual is released. 
‘‘(ii) EXCEPTION.—If a State makes a 
determination that an individual is not eli-
gible to be enrolled under the State plan— 
‘‘(I) on or before the date by 
which the individual would be enrolled 
under clause (i), such clause shall not 
apply to such individual; or 
‘‘(II) after such date, the State 
may terminate the enrollment of such 
individual. 
‘‘(B) RELATIONSHIP OF ENROLLMENT TO 
PAYMENT FOR SERVICES.— 
‘‘(i) IN
GENERAL.—Subject to sub-
paragraph (A)(ii), an eligible individual 
who is enrolled, or whose enrollment is re-
instated, under subparagraph (A) shall be 
eligible for all services for which medical 
assistance is provided under the State plan 
after the date that the eligible individual is 
released from the public institution. 
‘‘(ii) RELATIONSHIP
TO
PAYMENT 
PROHIBITION FOR INMATES.—No provision 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01269
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1270 
of this paragraph may be construed to per-
mit payment for care or services for which 
payment is excluded under subdivision (A) 
following the last numbered paragraph of 
section 1905(a). 
‘‘(C) TREATMENT OF CONTINUOUS ELIGI-
BILITY.— 
‘‘(i) SUSPENSION FOR INMATES.—Any 
period of continuous eligibility under this 
title shall be suspended on the date an in-
dividual enrolled under this title becomes 
an inmate of a public institution (except as 
a patient of a medical institution). 
‘‘(ii) DETERMINATION OF REMAINING 
PERIOD.—Notwithstanding any changes to 
State law related to continuous eligibility 
during the time that an individual is an in-
mate of a public institution (except as a 
patient of a medical institution), subject to 
clause (iii), with respect to an eligible indi-
vidual who was subject to a suspension 
under clause (i), on the date that such in-
dividual is released from a public institu-
tion the suspension of continuous eligibility 
under such clause shall be lifted for a pe-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01270
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1271 
riod that is equal to the time remaining in 
the period of continuous eligibility for such 
individual on the date that such period was 
suspended under such clause. 
‘‘(iii) EXCEPTION.—If a State makes 
a determination that an individual is not 
eligible to be enrolled under the State 
plan— 
‘‘(I) on or before the date that 
the suspension of continuous eligibility 
is lifted under clause (ii), such clause 
shall not apply to such individual; or 
‘‘(II) after such date, the State 
may terminate the enrollment of such 
individual. 
‘‘(D) AUTOMATIC ENROLLMENT OR REIN-
STATEMENT OF ENROLLMENT DEFINED.—For 
purposes of this paragraph, the term ‘automatic 
enrollment or reinstatement of enrollment’ 
means that the State determines eligibility for 
medical assistance under the State plan without 
a program application from, or on behalf of, the 
eligible individual, but an individual can only be 
automatically enrolled in the State Medicaid 
plan if the individual affirmatively consents to 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01271
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1272 
being enrolled through affirmation in writing, 
by telephone, orally, through electronic signa-
ture, or through any other means specified by 
the Secretary. 
‘‘(E) ELIGIBLE
INDIVIDUAL
DEFINED.— 
For purposes of this paragraph, the term ‘eligi-
ble individual’ means an individual who is an 
inmate of a public institution (except as a pa-
tient in a medical institution)— 
‘‘(i) who was enrolled under the State 
plan for medical assistance immediately be-
fore becoming an inmate of such an insti-
tution; or 
‘‘(ii) who is diagnosed with human im-
munodeficiency virus.’’. 
(b) SUPPLEMENTAL FUNDING FOR STATE IMPLE-
MENTATION OF AUTOMATIC REINSTATEMENT OF MED-
ICAID BENEFITS.— 
(1) IN GENERAL.—Subject to paragraph (3), 
with respect to a State, for each of the first 4 cal-
endar quarters in which the State plan meets the re-
quirements of paragraph (17) of section 1902(e) of 
the Social Security Act (42 U.S.C. 1396a(e)) (as 
added by subsection (a)), the Federal matching pay-
ments (including payments based on the Federal 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01272
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1273 
medical assistance percentage) made to such State 
under section 1903 of the Social Security Act (42 
U.S.C. 1396b) for the State expenditures described 
in paragraph (2) shall be increased by 5 percentage 
points. 
(2) EXPENDITURES.—The expenditures de-
scribed in this paragraph are the following: 
(A) Expenditures for which payment is 
available under section 1903 of the Social Secu-
rity Act (42 U.S.C. 1396b) and which are at-
tributable to strengthening the State’s enroll-
ment and administrative resources for the pur-
pose of improving processes for enrolling (or re-
instating the enrollment of) eligible individuals 
(as such term is defined in subparagraph (E) of 
paragraph (16) of section 1902(e) of the Social 
Security Act (42 U.S.C. 1396a(e)) (as amended 
by subsection (a))). 
(B) Expenditures for medical assistance 
(as such term is defined in section 1905(a) of 
the Social Security Act (42 U.S.C. 1396d(a))) 
provided to such eligible individuals. 
(3) REQUIREMENTS; LIMITATION.— 
(A) REPORT.—A State is not eligible for 
an increase in its Federal matching payments 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01273
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1274 
under paragraph (1) unless the State agrees to 
submit to the Secretary of Health and Human 
Services, and make publicly available, a report 
that contains the information required under 
paragraph (4) by the end of the 1-year period 
during which the State receives increased Fed-
eral matching payments in accordance with that 
paragraph. 
(B) MAINTENANCE OF ELIGIBILITY.— 
(i) IN
GENERAL.—Subject to clause 
(ii), a State is not eligible for an increase 
in its Federal matching payments under 
paragraph (1) if eligibility standards, 
methodologies, or procedures under its 
State plan under title XIX of the Social 
Security Act (42 U.S.C. 1396 et seq.), or 
waiver of such a plan, are more restrictive 
than the eligibility standards, methodolo-
gies, or procedures, respectively, under 
such plan or waiver as in effect on the date 
of enactment of this Act. 
(ii) STATE REINSTATEMENT OF ELIGI-
BILITY PERMITTED.—A State that has re-
stricted eligibility standards, methodolo-
gies, or procedures under its State plan 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01274
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1275 
under title XIX of the Social Security Act 
(42 U.S.C. 1396 et seq.), or a waiver of 
such plan, after the date of enactment of 
this Act, is no longer ineligible under 
clause (i) beginning with the first calendar 
quarter in which the State has reinstated 
eligibility standards, methodologies, or pro-
cedures that are no more restrictive than 
the eligibility standards, methodologies, or 
procedures, respectively, under such plan 
(or waiver) as in effect on such date. 
(C) LIMITATION OF MATCHING PAYMENTS 
TO 100 PERCENT.—In no case shall an increase 
in Federal matching payments under paragraph 
(1) result in Federal matching payments that 
exceed 100 percent of State expenditures. 
(4) REQUIRED REPORT INFORMATION.—The in-
formation that is required in the report under para-
graph (3)(A) shall include— 
(A) the results of an evaluation of the im-
pact of the implementation of the requirements 
of paragraph (17) of section 1902(e) of the So-
cial Security Act (42 U.S.C. 1396a(e)) on im-
proving the State’s processes for enrolling indi-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01275
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1276 
viduals who are released from public institu-
tions under the State Medicaid plan; 
(B) the number of individuals who were 
automatically enrolled (or whose enrollment was 
reinstated) under such paragraph during the 1- 
year period during which the State received in-
creased payments under this subsection; and 
(C) any other information that is required 
by the Secretary of Health and Human Serv-
ices. 
(c) EFFECTIVE DATE.— 
(1) IN GENERAL.—Except as provided in para-
graph (2), the amendments made by subsection (a) 
shall take effect 180 days after the date of the en-
actment of this Act. 
(2) RULE
FOR
CHANGES
REQUIRING
STATE 
LEGISLATION.—In the case of a State plan for med-
ical assistance under title XIX of the Social Security 
Act (42 U.S.C. 1396 et seq.) which the Secretary of 
Health and Human Services determines requires 
State legislation (other than legislation appro-
priating funds) in order for the plan to meet the ad-
ditional requirement imposed by the amendments 
made by subsection (a), the State plan shall not be 
regarded as failing to comply with the requirements 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01276
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1277 
of such title solely on the basis of its failure to meet 
this additional requirement before the first day of 
the first calendar quarter beginning after the close 
of the first regular session of the State legislature 
that begins after the date of the enactment of this 
Act. For purposes of the previous sentence, in the 
case of a State that has a 2-year legislative session, 
each year of such session shall be deemed to be a 
separate regular session of the State legislature. 
SEC. 7417. STOP HIV IN PRISON. 
(a) HIV POLICY.—The Director of the Bureau of 
Prisons (referred to in this section as the ‘‘Director’’) shall 
develop a comprehensive policy to provide HIV testing, 
treatment, and prevention for inmates within the correc-
tional setting and upon reentry. 
(b) PURPOSE.—The purposes of the policy required 
to be developed under subsection (a) shall be as follows: 
(1) To stop the spread of HIV among inmates. 
(2) To protect guards and other personnel at 
correctional facilities from HIV infection. 
(3) To provide comprehensive medical treat-
ment to inmates who are living with HIV. 
(4) To promote HIV awareness and prevention 
among inmates. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01277
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1278 
(5) To encourage inmates to take personal re-
sponsibility for their health. 
(6) To reduce the risk that inmates will trans-
mit HIV to other persons in the community fol-
lowing their release from a correctional facility. 
(c) CONSULTATION.—The Director shall consult with 
appropriate officials of the Department of Health and 
Human Services, the Office of National Drug Control Pol-
icy, the Office of National AIDS Policy, and the Centers 
for Disease Control and Prevention regarding the develop-
ment of the policy required under subsection (a). 
(d) TIME LIMIT.—Not later than 1 year after the 
date of enactment of this Act, the Director shall draft ap-
propriate regulations to implement the policy required to 
be developed under subsection (a). 
(e) REQUIREMENTS
FOR POLICY.—The policy re-
quired to be developed under subsection (a) shall provide 
for the following: 
(1) TESTING
AND
COUNSELING
UPON
IN-
TAKE.— 
(A) Health care personnel shall provide 
routine HIV testing to all inmates as a part of 
a comprehensive medical examination imme-
diately following admission to a facility. Health 
care personnel need not provide routine HIV 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01278
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1279 
testing to an inmate who is transferred to a fa-
cility from another facility if the inmate’s med-
ical records are transferred with the inmate and 
indicate that the inmate has been tested pre-
viously. 
(B) With respect to all inmates admitted 
to a facility prior to the effective date of the 
policy— 
(i) health care personnel shall provide 
routine HIV testing by not later than 180 
days after such effective date; and 
(ii) HIV testing described in clause (i) 
may be performed in conjunction with 
other health services provided to these in-
mates by health care personnel. 
(C) All HIV tests under this paragraph 
shall comply with the opt-out provision under 
paragraph (9). 
(2) PRE-TEST AND POST-TEST COUNSELING.— 
Health care personnel shall provide confidential pre- 
test and post-test counseling to all inmates who are 
tested for HIV. Counseling may be included with 
other general health counseling provided to inmates 
by health care personnel. 
(3) HIV PREVENTION EDUCATION.— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01279
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1280 
(A) Health care personnel shall improve 
HIV awareness through frequent educational 
programs for all inmates. HIV educational pro-
grams may be provided by community-based or-
ganizations, local health departments, and in-
mate peer educators. 
(B) HIV educational materials shall be 
made available to all inmates at orientation, at 
health care clinics, at regular educational pro-
grams, and prior to release. Both written and 
audiovisual materials shall be made available to 
all inmates. 
(C)(i) The HIV educational programs and 
materials under this paragraph shall include in-
formation on— 
(I) modes of transmission, including 
transmission through tattooing, sexual con-
tact, and intravenous drug use; 
(II) prevention methods; 
(III) treatment; and 
(IV) disease progression. 
(ii) The programs and materials shall be 
culturally sensitive, written or designed for low- 
literacy levels, available in a variety of lan-
guages, and present scientifically accurate in-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01280
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1281 
formation in a clear and understandable man-
ner. 
(4) HIV TESTING UPON REQUEST.— 
(A) Health care personnel shall allow in-
mates to obtain HIV tests upon request once 
per year or whenever an inmate has a reason to 
believe the inmate may have been exposed to 
HIV. Health care personnel shall, both orally 
and in writing, inform inmates, during orienta-
tion and periodically throughout incarceration, 
of their right to obtain HIV tests. 
(B) Health care personnel shall encourage 
inmates to request HIV tests if the inmate is 
sexually active, has been raped, uses intra-
venous drugs, receives a tattoo, or if the inmate 
is concerned that the inmate may have been ex-
posed to HIV. 
(C) An inmate’s request for an HIV test 
shall not be considered an indication that the 
inmate has put themselves at risk of infection 
or committed a violation of the rules of the cor-
rectional facility. 
(5) HIV TESTING OF PREGNANT WOMAN.— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01281
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1282 
(A) Health care personnel shall provide 
routine HIV testing to all inmates who become 
pregnant. 
(B) All HIV tests under this paragraph 
shall comply with the opt-out provision under 
paragraph (9). 
(6) COMPREHENSIVE TREATMENT.— 
(A) Health care personnel shall provide all 
inmates who test positive for HIV— 
(i) 
timely, 
comprehensive 
medical 
treatment; 
(ii) confidential counseling on man-
aging their medical condition and pre-
venting its transmission to other persons; 
and 
(iii) voluntary partner notification 
services. 
(B) Health care provided under this para-
graph shall be consistent with Department of 
Health and Human Services guidelines and 
standard medical practice. Health care per-
sonnel shall discuss treatment options, the im-
portance of adherence to antiretroviral therapy, 
and the side effects of medications with inmates 
receiving treatment. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01282
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1283 
(C) Health care personnel and pharmacy 
personnel shall ensure that the facility for-
mulary contains all Food and Drug Administra-
tion-approved medications necessary to provide 
comprehensive treatment for inmates living with 
HIV, and that the facility maintains adequate 
supplies of such medications to meet inmates’ 
medical needs. Health care personnel and phar-
macy personnel shall also develop and imple-
ment automatic renewal systems for these medi-
cations to prevent interruptions in care. 
(D) Correctional staff, health care per-
sonnel, and pharmacy personnel shall develop 
and implement distribution procedures to en-
sure timely and confidential access to medica-
tions. 
(7) PROTECTION OF CONFIDENTIALITY.— 
(A) Health care personnel shall develop 
and implement procedures to ensure the con-
fidentiality of inmate tests, diagnoses, and 
treatment. Health care personnel and correc-
tional staff shall receive regular training on the 
implementation of these procedures. Penalties 
for violations of inmate confidentiality by health 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01283
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1284 
care personnel or correctional staff shall be 
specified and strictly enforced. 
(B) HIV testing, counseling, and treat-
ment shall be provided in a confidential setting 
where other routine health services are provided 
and in a manner that allows the inmate to re-
quest and obtain these services as routine med-
ical services. 
(8) TESTING, COUNSELING, AND
REFERRAL 
PRIOR TO REENTRY.— 
(A) Health care personnel shall provide 
routine HIV testing to all inmates not earlier 
than 90 days prior to their release and reentry 
into the community. Inmates who are already 
known to be infected need not be tested again. 
This requirement may be waived if an inmate’s 
release occurs without sufficient notice to the 
Director to allow health care personnel to per-
form a routine HIV test and notify the inmate 
of the results. 
(B) All HIV tests under this paragraph 
shall comply with the opt-out provision under 
paragraph (9). 
(C) With respect to all inmates who test 
positive for HIV and all inmates who already 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01284
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1285 
are known to have HIV, health care personnel 
shall provide— 
(i) confidential prerelease counseling 
on managing their medical condition in the 
community, accessing appropriate treat-
ment and services in the community, and 
preventing the transmission of their condi-
tion to family members and other persons 
in the community; 
(ii) referrals to appropriate health 
care providers and social service agencies 
in the community that meet the inmate’s 
individual needs, including voluntary part-
ner notification services and prevention 
counseling services for people living with 
HIV; and 
(iii) a 30-day supply of any medically 
necessary medications the inmate is cur-
rently receiving. 
(9) OPT-OUT PROVISION.—Inmates shall have 
the right to refuse routine HIV testing. Inmates 
shall be informed both orally and in writing of this 
right. Oral and written disclosure of this right may 
be included with other general health information 
and counseling provided to inmates by health care 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01285
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1286 
personnel. If an inmate refuses a routine test for 
HIV, health care personnel shall make a note of the 
inmate’s refusal in the inmate’s confidential medical 
records. However, the inmate’s refusal shall not be 
considered a violation of the rules of the correctional 
facility or result in disciplinary action. 
(10) EXCLUSION OF TESTS PERFORMED UNDER 
SECTION 4014(b) FROM THE DEFINITION OF ROU-
TINE
HIV
TESTING.—HIV testing of an inmate 
under section 4014(b) of title 18, United States 
Code, is not routine HIV testing for the purposes of 
the opt-out provision under paragraph (9). Health 
care personnel shall document the reason for testing 
under section 4014(b) of title 18, United States 
Code, in the inmate’s confidential medical records. 
(11) TIMELY
NOTIFICATION
OF
TEST
RE-
SULTS.—Health care personnel shall provide timely 
notification to inmates of the results of HIV tests. 
(f) CHANGES IN EXISTING LAW.— 
(1) SCREENING IN GENERAL.—Section 4014(a) 
of title 18, United States Code, is amended— 
(A) by striking ‘‘for a period of 6 months 
or more’’; 
(B) by striking ‘‘, as appropriate,’’; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01286
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1287 
(C) by striking ‘‘if such individual is deter-
mined to be at risk for infection with such virus 
in accordance with the guidelines issued by the 
Bureau of Prisons relating to infectious disease 
management.’’ and inserting ‘‘unless the indi-
vidual declines. The Attorney General shall also 
cause such individual to be so tested before re-
lease from that incarceration unless the indi-
vidual declines.’’. 
(2) INADMISSIBILITY OF HIV TEST RESULTS IN 
CIVIL
AND
CRIMINAL
PROCEEDINGS.—Section 
4014(d) of title 18, United States Code, is amended 
by inserting ‘‘or under section 7417 of the Health 
Equity and Accountability Act of 2024’’ after 
‘‘under this section’’. 
(3) SCREENING AS PART OF ROUTINE SCREEN-
ING.—Section 4014(e) of title 18, United States 
Code, is amended by adding at the end the fol-
lowing: ‘‘Such rules shall also provide that the initial 
test under this section be performed as part of the 
routine health screening conducted at intake.’’. 
(g) REPORTING REQUIREMENTS.— 
(1) REPORT ON HEPATITIS, LIVER, AND OTHER 
DISEASES.—Not later than 1 year after the date of 
enactment of this Act, the Director shall submit to 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01287
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1288 
Congress a report on the policies and procedures of 
the Bureau of Prisons to provide testing, treatment, 
and prevention education programs for hepatitis, 
liver failure, and other liver-related diseases trans-
mitted through sexual activity, intravenous drug use, 
or other means. The Director shall consult with ap-
propriate officials of the Department of Health and 
Human Services, the Office of National Drug Con-
trol Policy, the Office of National AIDS Policy, and 
the Centers for Disease Control and Prevention re-
garding the development of this report. 
(2) ANNUAL REPORTS.— 
(A) GENERALLY.—Not later than 2 years 
after the date of enactment of this Act, and an-
nually thereafter, the Director submit to Con-
gress a report on the incidence among inmates 
of diseases transmitted through sexual activity 
and intravenous drug use. 
(B) MATTERS
PERTAINING
TO
VARIOUS 
DISEASES.—Each report under subparagraph 
(A) shall discuss— 
(i) the incidence among inmates of 
HIV, hepatitis, and other diseases trans-
mitted through sexual activity and intra-
venous drug use; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01288
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1289 
(ii) updates on the testing, treatment, 
and prevention education programs for 
these diseases conducted by the Bureau of 
Prisons. 
(C) 
MATTERS
PERTAINING
TO
HIV 
ONLY.—Each report under subparagraph (A) 
shall also include— 
(i) the number of inmates who tested 
positive for HIV upon intake; 
(ii) the number of inmates who tested 
positive for HIV prior to reentry; 
(iii) the number of inmates who were 
not tested for HIV prior to reentry because 
they were released without sufficient no-
tice; 
(iv) the number of inmates who opted 
out of taking an HIV test; 
(v) the number of inmates who were 
tested under section 4014(b) of title 18, 
United States Code; and 
(vi) the number of inmates under 
treatment for HIV. 
(D) CONSULTATION.—The Director shall 
consult with appropriate officials of the Depart-
ment of Health and Human Services, the Office 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01289
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1290 
of National Drug Control Policy, the Office of 
National AIDS Policy, and the Centers for Dis-
ease Control and Prevention regarding the de-
velopment of each report under subparagraph 
(A). 
SEC. 7418. TRANSFER OF FUNDS FOR IMPLEMENTATION OF 
ENDING THE HIV EPIDEMIC: A PLAN FOR 
AMERICA. 
Title II of the Public Health Service Act (42 U.S.C. 
202 et seq.) is amended by inserting after section 241 (42 
U.S.C. 238j) the following: 
‘‘SEC. 241A. TRANSFER OF FUNDS FOR IMPLEMENTATION 
OF NATIONAL HIV/AIDS STRATEGY. 
‘‘(a) TRANSFER AUTHORIZATION.—Of the discre-
tionary appropriations made available to the Department 
of Health and Human Services for any fiscal year for pro-
grams and activities that, as determined by the Secretary, 
pertain to HIV, the Secretary may transfer up to 1 per-
cent of such appropriations to the Office of the Assistant 
Secretary for Health for implementation of the Ending the 
HIV Epidemic: A Plan for America. 
‘‘(b) CONGRESSIONAL NOTIFICATION.—Not less than 
30 days before making any transfer under this section, 
the Secretary shall give notice of the transfer to the Con-
gress. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01290
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1291 
‘‘(c) DEFINITIONS.—In this section, the term ‘End-
ing the HIV Epidemic: A Plan for America’ means the 
initiative of the Department of Health and Human Serv-
ices that seeks to reduce the number of new HIV infec-
tions in the United States by 75 percent by 2025, and 
then by at least 90 percent by 2030, for an estimated 
250,000 total HIV infections averted.’’. 
SEC. 7419. PrEP ACCESS AND COVERAGE. 
(a) COVERAGE OF HIV TESTING AND PREVENTION 
SERVICES.— 
(1) PRIVATE INSURANCE.— 
(A) IN GENERAL.—Section 2713(a) of the 
Public Health Service Act (42 U.S.C. 300gg– 
13(a)) is amended— 
(i) in paragraph (2), by striking ‘‘; 
and’’ and inserting a semicolon; 
(ii) in paragraph (3), by striking the 
period and inserting a semicolon; 
(iii) in paragraph (4), by striking the 
period and inserting a semicolon; 
(iv) in paragraph (5), by striking the 
period and inserting ‘‘; and’’; and 
(v) by adding at the end the following: 
‘‘(6) any prescription drug approved by the 
Food and Drug Administration for the prevention of 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01291
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1292 
HIV (other than a drug subject to preauthorization 
requirements consistent with section 2729A), admin-
istrative fees for such drugs, laboratory and other 
diagnostic procedures associated with the use of 
such drugs, and clinical follow-up and monitoring, 
including any related services recommended in cur-
rent United States Public Health Service clinical 
practice guidelines, without limitation.’’. 
(B) PROHIBITION ON PREAUTHORIZATION 
REQUIREMENTS.—Subpart II of part A of title 
XXVII of the Public Health Service Act (42 
U.S.C. 300gg–11 et seq.) is amended by adding 
at the end the following: 
‘‘SEC. 2729A. PROHIBITION ON PREAUTHORIZATION RE-
QUIREMENTS WITH RESPECT TO CERTAIN 
SERVICES. 
‘‘A group health plan or a health insurance issuer of-
fering group or individual health insurance coverage shall 
not impose any preauthorization requirements with re-
spect to coverage of the services described in section 
2713(a)(1)(E), except that a plan or issuer may impose 
preauthorization requirements with respect to coverage of 
a particular drug approved under section 505(c) of the 
Federal Food, Drug, and Cosmetic Act or section 351(a) 
of this Act if such plan or issuer provides coverage without 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01292
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1293 
any preauthorization requirements for a drug that is ther-
apeutically equivalent.’’. 
(2) COVERAGE
UNDER
FEDERAL
EMPLOYEES 
HEALTH BENEFITS PROGRAM.—Section 8904 of title 
5, United States Code, is amended by adding at the 
end the following: 
‘‘(c) Any health benefits plan offered under this chap-
ter shall include benefits for, and may not impose any cost 
sharing requirements for, any prescription drug approved 
by the Food and Drug Administration for the prevention 
of HIV, administrative fees for such drugs, laboratory and 
other diagnostic procedures associated with the use of 
such drugs, and clinical follow-up and monitoring, includ-
ing any related services recommended in current United 
States Public Health Service clinical practice guidelines, 
without limitation.’’. 
(3) MEDICAID.— 
(A) IN GENERAL.—Section 1905 of the So-
cial Security Act (42 U.S.C. 1396d), as amend-
ed by section 5406(g), is amended— 
(i) in subsection (a)(4)— 
(I) by striking ‘‘; and (G)’’ and 
inserting ‘‘; (G)’’; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01293
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1294 
(II) by striking the semicolon at 
the end and inserting ‘‘; and (H) HIV 
prevention services;’’; and 
(ii) by adding at the end the following 
new subsection: 
‘‘(rr) HIV PREVENTION SERVICES.—For purposes of 
subsection (a)(4)(H), the term ‘HIV prevention services’ 
means prescription drugs for the prevention of HIV acqui-
sition, administrative fees for such drugs, laboratory and 
other diagnostic procedures associated with the use of 
such drugs, and clinical follow-up and monitoring, includ-
ing any related services recommended in current United 
States Public Health Service clinical practice guidelines, 
without limitation.’’. 
(B) NO COST-SHARING.—Title XIX of the 
Social Security Act (42 U.S.C. 1396 et seq.) is 
amended— 
(i) in section 1916, by inserting ‘‘HIV 
prevention services described in section 
1905(a)(4)(H),’’ 
after 
‘‘section 
1905(a)(4)(C),’’ each place it appears; and 
(ii) in section 1916A(b)(3)(B), as 
amended by section 7305, by adding at the 
end the following new clause: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01294
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1295 
‘‘(xvi) HIV prevention services de-
scribed in section 1905(a)(4)(H).’’. 
(C) INCLUSION
IN
BENCHMARK
COV-
ERAGE.—Section 1937(b)(7) of the Social Secu-
rity Act (42 U.S.C. 1396u–7(b)(7)) is amend-
ed— 
(i) in the paragraph header, by insert-
ing ‘‘AND
HIV
PREVENTION
SERVICES’’ 
after ‘‘SUPPLIES’’; and 
(ii) by striking ‘‘includes for any indi-
vidual described in section 1905(a)(4)(C), 
medical assistance for family planning 
services and supplies in accordance with 
such section’’ and inserting ‘‘includes med-
ical assistance for HIV prevention services 
described in section 1905(a)(4)(H), and in-
cludes, for any individual described in sec-
tion 1905(a)(4)(H), medical assistance for 
family planning services and supplies in ac-
cordance with such section’’. 
(4) CHIP.— 
(A) IN GENERAL.—Section 2103 of the So-
cial Security Act (42 U.S.C. 1397cc), as 
amended by section 2007(d)(5), is amended— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01295
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1296 
(i) in subsection (a), by striking 
‘‘through (13)’’ and inserting ‘‘through 
(14)’’; and 
(ii) in subsection (c), by adding at the 
end the following new paragraph: 
‘‘(14) HIV PREVENTION
SERVICES.—Regard-
less of the type of coverage elected by a State under 
subsection (a), the child health assistance provided 
for a targeted low-income child, and, in the case of 
a State that elects to provide pregnancy-related as-
sistance pursuant to section 2112, the pregnancy-re-
lated assistance provided for a targeted low-income 
pregnant woman (as such terms are defined for pur-
poses of such section), shall include coverage of HIV 
prevention 
services 
(as 
defined 
in 
section 
1905(rr)).’’. 
(B) 
NO
COST-SHARING.—Section 
2103(e)(2) of the Social Security Act (42 
U.S.C. 1397cc(e)(2)) is amended by inserting 
‘‘HIV prevention services described in sub-
section (c)(14),’’ before ‘‘or for pregnancy-re-
lated assistance’’. 
(C) EFFECTIVE DATE.— 
(i) IN
GENERAL.—Subject to clause 
(ii), the amendments made by paragraph 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01296
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1297 
(3) and this paragraph shall take effect on 
January 1, 2025. 
(ii) DELAY PERMITTED IF STATE LEG-
ISLATION
REQUIRED.—In the case of a 
State plan approved under title XIX or 
XXI of the Social Security Act which the 
Secretary of Health and Human Services 
determines requires State legislation (other 
than legislation appropriating funds) in 
order for the plan to meet the additional 
requirements imposed by this subsection, 
the State plan shall not be regarded as 
failing to comply with the requirements of 
such title solely on the basis of the failure 
of the plan to meet such additional re-
quirements before the 1st day of the 1st 
calendar quarter beginning after the close 
of the 1st regular session of the State leg-
islature that ends after the 1-year period 
beginning with the date of the enactment 
of this Act. For purposes of the preceding 
sentence, in the case of a State that has a 
2-year legislative session, each year of the 
session is deemed to be a separate regular 
session of the State legislature. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01297
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1298 
(5) COVERAGE
AND
ELIMINATION
OF
COST- 
SHARING UNDER MEDICARE.— 
(A) COVERAGE OF HIV PREVENTION SERV-
ICES UNDER PART B.— 
(i) COVERAGE.— 
(I) 
IN
GENERAL.—Section 
1861(s)(2) of the Social Security Act 
(42 U.S.C. 1395x(s)(2)), as amended 
by section 4251(c)(1) and 6101(a)(1), 
is amended— 
(aa) by striking ‘‘and’’ at 
the end of subparagraph (KK); 
(bb) by inserting ‘‘and’’ at 
the end of subparagraph (LL); 
and 
(cc) by adding at the end 
the following new subparagraph: 
‘‘(MM) HIV prevention services (as defined in 
subsection (ppp));’’. 
(II) DEFINITION.—Section 1861 
of the Social Security Act (42 U.S.C. 
1395x), as amended by sections 
2007(b), 4221(a), 4251(c)(2), and 
6101(a)(2), is amended by adding at 
the end the following new subsection: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01298
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1299 
‘‘(rrr) HIV PREVENTION SERVICES.—The term ‘HIV 
prevention services’ means— 
‘‘(1) drugs or biologicals approved by the Food 
and Drug Administration for the prevention of HIV; 
‘‘(2) administrative fees for such drugs; 
‘‘(3) laboratory and other diagnostic procedures 
associated with the use of such drugs; and 
‘‘(4) clinical follow-up and monitoring, including 
any related services recommended in current United 
States Public Health Service clinical practice guide-
lines, without limitation.’’. 
(ii) ELIMINATION OF COINSURANCE.— 
Section 1833(a)(1) of the Social Security 
Act (42 U.S.C. 1395l(a)(1)), as amended 
by sections 4251(c)(3) and 6101(a)(4), is 
amended— 
(I) by striking ‘‘and’’ before 
‘‘(JJ)’’; and 
(II) by inserting before the semi-
colon at the end the following: ‘‘and 
(KK) with respect to HIV prevention 
services 
(as 
defined 
in 
section 
1861(rrr)), the amount paid shall be 
100 percent of (i) except as provided 
in clause (ii), the lesser of the actual 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01299
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1300 
charge for the service or the amount 
determined under the fee schedule 
that applies to such services under 
this part, and (ii) in the case of such 
services that are covered OPD serv-
ices 
(as 
defined 
in 
subsection 
(t)(1)(B)), the amount determined 
under subsection (t)’’. 
(iii) EXEMPTION FROM PART B DE-
DUCTIBLE.—Section 1833(b) of the Social 
Security Act (42 U.S.C. 1395l(b)) is 
amended— 
(I) in paragraph (12), by striking 
‘‘section 1861(s)(10)(A),, and’’ and 
inserting ‘‘section 1861(s)(10)(A),’’; 
(II) in paragraph (13), by strik-
ing ‘‘section 1861(n)..’’ and inserting 
‘‘section 1861(n), and (14) such de-
ductible shall not apply with respect 
to HIV prevention services (as defined 
in section 1861(rrr).’’. 
(iv) EFFECTIVE DATE.—The amend-
ments made by this subparagraph shall 
apply to items and services furnished on or 
after January 1, 2025. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01300
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1301 
(B) ELIMINATION OF COST-SHARING FOR 
DRUGS FOR THE PREVENTION OF HIV UNDER 
PART D.— 
(i) IN
GENERAL.—Section 1860D–2 
of the Social Security Act (42 U.S.C. 
1395w–102) is amended— 
(I) in subsection (b)— 
(aa) in paragraph (1)(A), in 
the matter preceding clause (i), 
by striking ‘‘(8) and (9)’’ and in-
serting ‘‘(8), (9), and (10)’’; 
(bb) in paragraph (2)(A), in 
subparagraph (A), in the matter 
preceding clause (i), by striking 
‘‘(8) and (9)’’ and inserting ‘‘(8), 
(9), and (10)’’; and 
(cc) by adding at the end 
the following new paragraph: 
‘‘(10) ELIMINATION
OF
COST-SHARING
FOR 
DRUGS FOR THE PREVENTION OF HIV.—For plan 
years beginning on or after January 1, 2025, with 
respect to a covered part D drug that is for the pre-
vention of HIV— 
‘‘(A) the deductible under paragraph (1) 
shall not apply; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01301
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1302 
‘‘(B) there shall be no coinsurance or other 
cost-sharing under this part with respect to 
such drug.’’; and 
(II) in subsection (c), by adding 
at the end the following new para-
graph: 
‘‘(7) 
TREATMENT
OF
COST-SHARING
FOR 
DRUGS FOR THE PREVENTION OF HIV.—The cov-
erage is in accordance with subsection (b)(10).’’. 
(ii) CONFORMING
AMENDMENTS
TO 
COST-SHARING FOR LOW-INCOME INDIVID-
UALS.—Section 1860D–14(a)(1)(D) of the 
Social Security Act (42 U.S.C. 1395w– 
114(a)(1)(D)) is amended in each of 
clauses (ii) and (iii), by striking ‘‘para-
graph (6)’’ and inserting ‘‘paragraph (6) 
and section 1860D–2(b)(10)’’. 
(6) COVERAGE
OF
HIV
PREVENTION
TREAT-
MENT BY DEPARTMENT OF VETERANS AFFAIRS.— 
(A) ELIMINATION OF MEDICATION COPAY-
MENTS.—Section 1722A(a) of title 38, United 
States Code, is amended by adding at the end 
the following new paragraph: 
‘‘(5) Paragraph (1) does not apply to a medication 
for the prevention of HIV.’’. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01302
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1303 
(B) ELIMINATION OF HOSPITAL CARE AND 
MEDICAL
SERVICES
COPAYMENTS.—Section 
1710 of such title is amended— 
(i) in subsection (f)— 
(I) by redesignating paragraph 
(5) as paragraph (6); and 
(II) by inserting after paragraph 
(4) the following new paragraph (5): 
‘‘(5) A veteran shall not be liable to the United States 
under this subsection for any amounts for laboratory and 
other diagnostic procedures associated with the use of any 
prescription drug approved by the Food and Drug Admin-
istration for the prevention of HIV, administrative fees for 
such drugs, or for laboratory or other diagnostic proce-
dures associated with the use of such drugs, or clinical 
follow-up and monitoring, including any related services 
recommended in current United States Public Health 
Service clinical practice guidelines, without limitation.’’; 
and 
(ii) in subsection (g)(3), by adding at 
the end the following new subparagraph: 
‘‘(C) Any prescription drug approved by the 
Food and Drug Administration for the prevention of 
HIV, administrative fees for such drugs, laboratory 
and other diagnostic procedures associated with the 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01303
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1304 
use of such drugs, and clinical follow-up and moni-
toring, including any related services recommended 
in current United States Public Health Service clin-
ical practice guidelines, without limitation.’’. 
(C) INCLUSION
AS
PREVENTIVE
HEALTH 
SERVICE.—Section 1701(9) of such title is 
amended— 
(i) in subparagraph (K), by striking ‘‘; 
and’’ and inserting a semicolon; 
(ii) by redesignating subparagraph 
(L) as subparagraph (M); and 
(iii) by inserting after subparagraph 
(K) the following new subparagraph (L): 
‘‘(L) any prescription drug approved by 
the Food and Drug Administration for the pre-
vention of HIV, administrative fees for such 
drugs, laboratory and other diagnostic proce-
dures associated with the use of such drugs, 
and clinical follow-up and monitoring, including 
any related services recommended in current 
United States Public Health Service clinical 
practice guidelines, without limitation; and’’. 
(7) COVERAGE
OF
HIV
PREVENTION
TREAT-
MENT BY DEPARTMENT OF DEFENSE.— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01304
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1305 
(A) IN GENERAL.—Chapter 55 of title 10, 
United States Code, is amended by inserting 
after section 1079c the following new section: 
‘‘§ 1079d. Coverage of HIV prevention treatment 
‘‘(a) IN GENERAL.—The Secretary of Defense shall 
ensure coverage under the TRICARE program of HIV 
prevention treatment described in subsection (b) for any 
beneficiary under section 1074(a) of this title. 
‘‘(b) HIV PREVENTION TREATMENT DESCRIBED.— 
HIV prevention treatment described in this subsection in-
cludes any prescription drug approved by the Food and 
Drug Administration for the prevention of HIV, adminis-
trative fees for such drugs, laboratory and other diagnostic 
procedures associated with the use of such drugs, and clin-
ical follow-up and monitoring, including any related serv-
ices recommended in current United States Public Health 
Service clinical practice guidelines, without limitation. 
‘‘(c) NO COST-SHARING.—Notwithstanding section 
1075, 1075a, or 1074g(a)(6) of this title or any other pro-
vision of law, there is no cost-sharing requirement for HIV 
prevention treatment covered under this section.’’. 
(B) CLERICAL AMENDMENT.—The table of 
sections at the beginning of such chapter is 
amended by inserting after the item relating to 
section 1079c the following new item: 
‘‘1079d. Coverage of HIV prevention treatment.’’. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01305
Fmt 6652
Sfmt 6211
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1306 
(8) INDIAN HEALTH SERVICE TESTING, MONI-
TORING, AND PRESCRIPTION DRUGS FOR THE PRE-
VENTION OF HIV.—Title II of the Indian Health 
Care Improvement Act is amended by inserting after 
section 223 (25 U.S.C. 1621v) the following: 
‘‘SEC. 224. TESTING, MONITORING, AND PRESCRIPTION 
DRUGS FOR THE PREVENTION OF HIV. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Service, Indian tribes, and tribal organizations, shall 
provide, without limitation, funding for any prescription 
drug approved by the Food and Drug Administration for 
the prevention of human immunodeficiency virus (com-
monly known as ‘HIV’), administrative fees for that drug, 
laboratory and other diagnostic procedures associated with 
the use of that drug, and clinical follow-up and moni-
toring, including any related services recommended in cur-
rent Public Health Service clinical practice guidelines. 
‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated such sums as are nec-
essary to carry out this section.’’. 
(9) EFFECTIVE DATE.—The amendments made 
by paragraphs (1), (2), (5), (6), (7), and (8) shall 
take effect with respect to plan years beginning on 
or after January 1, 2025. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01306
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1307 
(b) PROHIBITION ON DENIAL OF COVERAGE OR IN-
CREASE IN PREMIUMS OF LIFE, DISABILITY, OR LONG- 
TERM
CARE
INSURANCE
FOR
INDIVIDUALS
TAKING 
MEDICATION FOR THE PREVENTION OF HIV ACQUISI-
TION.— 
(1) PROHIBITION.—Notwithstanding any other 
provision of law, it shall be unlawful to— 
(A) decline or limit coverage of a person 
under any life insurance policy, disability insur-
ance policy, or long-term care insurance policy, 
on account of the individual taking medication 
for the purpose of preventing the acquisition of 
HIV; 
(B) preclude an individual from taking 
medication for the purpose of preventing the ac-
quisition of HIV as a condition of receiving a 
life insurance policy, disability insurance policy, 
or long-term care insurance policy; 
(C) consider whether an individual is tak-
ing medication for the purpose of preventing 
the acquisition of HIV in determining the pre-
mium rate for coverage of such individual under 
a life insurance policy, disability insurance pol-
icy, or long-term care insurance policy; or 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01307
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1308 
(D) otherwise discriminate in the offering, 
issuance, cancellation, amount of such coverage, 
price, or any other condition of a life insurance 
policy, disability insurance policy, or long-term 
care insurance policy for an individual, based 
solely and without any additional actuarial risks 
upon whether the individual is taking medica-
tion for the purpose of preventing the acquisi-
tion of HIV. 
(2) ENFORCEMENT.—A State insurance regu-
lator may take such actions to enforce paragraph (1) 
as are specifically authorized under the laws of such 
State. 
(3) DEFINITIONS.—In this subsection: 
(A) DISABILITY INSURANCE POLICY.—The 
term ‘‘disability insurance policy’’ means a con-
tract under which an entity promises to pay a 
person a sum of money in the event that an ill-
ness or injury resulting in a disability prevents 
such person from working. 
(B) LIFE INSURANCE POLICY.—The term 
‘‘life insurance policy’’ means a contract under 
which an entity promises to pay a designated 
beneficiary a sum of money upon the death of 
the insured. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01308
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1309 
(C) LONG-TERM
CARE
INSURANCE
POL-
ICY.—The term ‘‘long-term care insurance pol-
icy’’ means a contract for which the only insur-
ance protection provided under the contract is 
coverage of qualified long-term care services (as 
defined in section 7702B(c) of the Internal 
Revenue Code of 1986). 
(c) PATIENT CONFIDENTIALITY.—The Secretary of 
Health and Human Services shall amend the regulations 
promulgated under section 264(c) of the Health Insurance 
Portability and Accountability Act of 1996 (42 U.S.C. 
1320d–2 note), as necessary, to ensure that individuals 
are able to access the benefits described in section 
2713(a)(1)(E) of the Public Health Service Act under a 
family plan without any other individual enrolled in such 
family plan, including a primary subscriber or policyholder 
of such plan, being informed of such use of such benefits. 
(d) PRE-EXPOSURE PROPHYLAXIS AND POST-EXPO-
SURE PROPHYLAXIS FUNDING.—Part P of title III of the 
Public Health Service Act (42 U.S.C. 280g et seq.), as 
amended by section 7303, is amended by adding at the 
end the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01309
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1310 
‘‘SEC. 399V–11. PRE-EXPOSURE PROPHYLAXIS AND POST-EX-
POSURE PROPHYLAXIS FUNDING. 
‘‘(a) IN GENERAL.—Not later than 1 year after the 
date of enactment of this section, the Secretary shall es-
tablish a program that awards grants to States, terri-
tories, Indian Tribes, and directly eligible entities for the 
establishment and support of pre-exposure prophylaxis 
(referred to in this section as ‘PrEP’) and post-exposure 
prophylaxis (referred to in this section as ‘PEP’) HIV pro-
grams. 
‘‘(b) APPLICATIONS.—To be eligible to receive a 
grant under subsection (a), a State, territory, Indian 
Tribe, or directly eligible entity shall— 
‘‘(1) submit an application to the Secretary at 
such time, in such manner, and containing such in-
formation as the Secretary may require, including a 
plan describing how any funds awarded will be used 
to increase access to PrEP for uninsured and under-
insured individuals and reduce disparities in access 
to PrEP and PEP for uninsured and underinsured 
individuals and reduce disparities in access to PrEP 
and PEP; and 
‘‘(2) appoint a PrEP and PEP grant adminis-
trator to manage the program. 
‘‘(c) DIRECTLY ELIGIBLE ENTITY.—For purposes of 
this section, the term ‘directly eligible entity’— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01310
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1311 
‘‘(1) means a Federally qualified health center 
or other nonprofit entity engaged in providing PrEP 
and PEP information and services; and 
‘‘(2) may include— 
‘‘(A) a Federally qualified health center 
(as defined in section 1861(aa)(4) of the Social 
Security Act (42 U.S.C. 1395x(aa)(4))); 
‘‘(B) a family planning grantee (other than 
States) funded under section 1001 of the Public 
Health Service Act (42 U.S.C. 300); 
‘‘(C) a rural health clinic (as defined in 
section 1861(aa)(2) of the Social Security Act 
(42 U.S.C. 1395x(aa)(2))); 
‘‘(D) a health facility operated by or pur-
suant to a contract with the Indian Health 
Service; 
‘‘(E) a community-based organization, clin-
ic, hospital, or other health facility that pro-
vides services to individuals at risk for or living 
with HIV; and 
‘‘(F) a nonprofit private entity providing 
comprehensive primary care to populations at 
risk of HIV, including faith-based and commu-
nity-based organizations. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01311
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1312 
‘‘(d) AWARDS.—In determining whether to award a 
grant, and the grant amount for each grant awarded, the 
Secretary shall consider the grant application and the 
need for PrEP and PEP services in the area, the number 
of uninsured and underinsured individuals in the area, and 
how the State, territory, or Indian Tribe coordinates 
PrEP and PEP activities with the directly funded entity, 
if the State, territory, or Indian Tribe applies for the 
funds. 
‘‘(e) USE OF FUNDS.— 
‘‘(1) IN GENERAL.—Any State, territory, Indian 
Tribe, or directly eligible entity that is awarded 
funds under subsection (a) shall use such funds for 
eligible PrEP and PEP expenses. 
‘‘(2) ELIGIBLE
PREP
EXPENSES.—The Sec-
retary shall publish a list of expenses that qualify as 
eligible PrEP and PEP expenses for purposes of this 
section, which shall include— 
‘‘(A) any prescription drug approved by 
the Food and Drug Administration for the pre-
vention of HIV, administrative fees for such 
drugs, laboratory and other diagnostic proce-
dures associated with the use of such drugs, 
and clinical follow-up and monitoring, including 
any related services recommended in current 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01312
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1313 
United States Public Health Service clinical 
practice guidelines, without limitation; 
‘‘(B) outreach and public education activi-
ties directed toward populations overrepresented 
in the domestic HIV epidemic that increase 
awareness about the existence of PrEP and 
PEP, provide education about access to and 
health care coverage of PrEP and PEP, PrEP 
and PEP adherence programs, and counter 
stigma associated with the use of PrEP and 
PEP; and 
‘‘(C) outreach activities directed toward 
physicians and other providers that provide 
education about PrEP and PEP. 
‘‘(f) REPORT TO CONGRESS.—The Secretary shall, in 
each of the first 5 years beginning one year after the date 
of the enactment of this section, submit to Congress, and 
make public on the internet website of the Department 
of Health and Human Services, a report on the impact 
of any grants provided to States, territories, and Indian 
Tribes and directly eligible entities for the establishment 
and support of pre-exposure prophylaxis programs under 
this section. 
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there are authorized to be appro-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01313
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1314 
priated such sums as may be necessary for each of fiscal 
years 2025 through 2030.’’. 
(e) CLARIFICATION.—This section, including the 
amendments made by this section, shall apply notwith-
standing any other provision of law, including Public Law 
103–141. 
(f) PRIVATE RIGHT OF ACTION.—Any person ag-
grieved by a violation of this section, including the amend-
ments made by this section, may commence a civil action 
in an appropriate United States District Court or other 
court of competent jurisdiction to obtain relief as allowed 
by law as either an individual or member of a class. If 
the plaintiff is the prevailing party in such an action, the 
court shall order the defendant to pay the costs and rea-
sonable attorney fees of the plaintiff. 
Subtitle F—Diabetes 
SEC. 7501. RESEARCH, TREATMENT, AND EDUCATION. 
Subpart 3 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 285c et seq.) is amended by adding 
at the end the following: 
‘‘SEC. 434B. DIABETES IN MINORITY POPULATIONS. 
‘‘(a) IN GENERAL.—The Director of NIH shall ex-
pand, intensify, and support ongoing research and other 
activities with respect to prediabetes and diabetes, particu-
larly type 2, in minority populations. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01314
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1315 
‘‘(b) RESEARCH.— 
‘‘(1) DESCRIPTION.—Research under subsection 
(a) shall include investigation into— 
‘‘(A) the causes of diabetes, including so-
cioeconomic, geographic, clinical, environmental, 
genetic, and other factors that may contribute 
to increased rates of diabetes in minority popu-
lations; and 
‘‘(B) the causes of increased incidence of 
diabetes complications in minority populations, 
and possible interventions to decrease such inci-
dence. 
‘‘(2) INCLUSION OF MINORITY PARTICIPANTS.— 
In conducting and supporting research described in 
subsection (a), the Director of NIH shall seek to in-
clude minority participants as study subjects in clin-
ical trials. 
‘‘(c) REPORT; COMPREHENSIVE PLAN.— 
‘‘(1) IN
GENERAL.—The Diabetes Mellitus 
Interagency Coordinating Committee shall— 
‘‘(A) prepare and submit to Congress, not 
later than 6 months after the date of enactment 
of this section, a report on Federal research 
and public health activities with respect to 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01315
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1316 
prediabetes and diabetes in minority popu-
lations; and 
‘‘(B) develop and submit to Congress, not 
later than 1 year after the date of enactment of 
this section, an effective and comprehensive 
Federal plan (including all appropriate Federal 
health programs) to address prediabetes and di-
abetes in minority populations. 
‘‘(2) CONTENTS.—The report under paragraph 
(1)(A) shall at minimum address each of the fol-
lowing: 
‘‘(A) Research on diabetes and prediabetes 
in minority populations, including such research 
on— 
‘‘(i) 
genetic, 
behavioral, 
socio-
economic, and environmental factors; 
‘‘(ii) prevention of diabetes within 
these populations and which of the popu-
lations have individuals at increased risk of 
developing diabetes; 
‘‘(iii) 
prevention 
of 
complications 
among individuals in these populations who 
have already developed diabetes; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01316
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1317 
‘‘(iv) barriers to health care access 
and diabetes treatment within populations 
at increased risk of developing diabetes. 
‘‘(B) Surveillance and data collection on 
diabetes and prediabetes in minority popu-
lations, including with respect to— 
‘‘(i) efforts to better determine the 
prevalence of diabetes among Asian-Amer-
ican and Pacific Islander subgroups; and 
‘‘(ii) efforts to coordinate data collec-
tion on the American Indian population. 
‘‘(C) Community-based interventions to ad-
dress diabetes and prediabetes targeting minor-
ity populations, including— 
‘‘(i) the evidence base for such inter-
ventions; 
‘‘(ii) the cultural appropriateness of 
such interventions; and 
‘‘(iii) efforts to educate the public on 
the causes and consequences of diabetes. 
‘‘(D) Education and training programs for 
health 
professionals 
(including 
community 
health workers) on the prevention and manage-
ment of diabetes and its related complications 
that is supported by the Health Resources and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01317
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1318 
Services Administration, including such pro-
grams supported by— 
‘‘(i) the National Health Service 
Corps; or 
‘‘(ii) the community health centers 
program under section 330. 
‘‘(d) EDUCATION.—The Director of NIH shall— 
‘‘(1) through the National Institute on Minority 
Health and Health Disparities and the National Di-
abetes Education Program— 
‘‘(A) make grants to programs funded 
under section 464z–4 for the purpose of estab-
lishing a medical education program for health 
care professionals to be more involved in weight 
counseling, obesity research, nutrition, and 
shared decision making; and 
‘‘(B) provide for the participation of mi-
nority health professionals in diabetes-focused 
research programs; and 
‘‘(2) make grants to programs that establish a 
professional pipeline that will increase the participa-
tion of minority individuals in diabetes-focused 
health fields by expanding Minority Access to Re-
search Careers program internships and mentoring 
opportunities for the purposes of recruitment. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01318
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1319 
‘‘(e) DEFINITIONS.—For purposes of this section: 
‘‘(1) DIABETES
MELLITUS
INTERAGENCY
CO-
ORDINATING
COMMITTEE.—The ‘Diabetes Mellitus 
Interagency Coordinating Committee’ means the Di-
abetes Mellitus Interagency Coordinating Committee 
established under section 429. 
‘‘(2) MINORITY POPULATION.—The term ‘mi-
nority population’ means a racial and ethnic minor-
ity group, as defined in section 1707.’’. 
SEC. 7502. RESEARCH, EDUCATION, AND OTHER ACTIVI-
TIES. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.), as amended by section 7201, is 
amended by inserting after section 317X the following: 
‘‘SEC. 317Y. DIABETES IN MINORITY POPULATIONS. 
‘‘(a) RESEARCH AND OTHER ACTIVITIES.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, shall conduct and support 
research and public health activities with respect to 
diabetes in minority populations. 
‘‘(2) CERTAIN
ACTIVITIES.—Activities under 
paragraph (1) regarding diabetes in minority popu-
lations shall include the following: 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01319
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1320 
‘‘(A) Further enhancing the National 
Health and Nutrition Examination Survey by 
oversampling Asian Americans, Native Hawai-
ians, and Pacific Islanders in appropriate geo-
graphic areas to better determine the preva-
lence of diabetes in such populations as well as 
to improve the data collection of diabetes pene-
tration disaggregated into major ethnic groups 
within such populations. The Secretary shall en-
sure that any such oversampling does not re-
duce the oversampling of other minority popu-
lations including African-American and Latino 
populations. 
‘‘(B) Through the Division of Diabetes 
Translation— 
‘‘(i) providing for prevention research 
to better understand how to influence 
health care systems changes to improve 
quality of care being delivered to such pop-
ulations; 
‘‘(ii) carrying out model demonstra-
tion projects to design, implement, and 
evaluate effective diabetes prevention and 
control interventions for minority popu-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01320
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1321 
lations, including culturally appropriate 
community-based interventions; 
‘‘(iii) developing and implementing a 
strategic plan to reduce diabetes in minor-
ity populations through applied research to 
reduce disparities and culturally and lin-
guistically appropriate community-based 
interventions; 
‘‘(iv) supporting, through the national 
diabetes prevention program under section 
399V–3, diabetes prevention program sites 
in underserved regions highly impacted by 
diabetes; and 
‘‘(v) implementing, through the na-
tional diabetes prevention program under 
section 399V–3, a demonstration program 
developing new metrics measuring health 
outcomes related to diabetes that can be 
stratified by specific minority populations. 
‘‘(b) EDUCATION.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, shall direct the Division of Diabetes Translation 
to conduct and support both programs to educate the pub-
lic on diabetes in minority populations and programs to 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01321
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1322 
educate minority populations about the causes and effects 
of diabetes. 
‘‘(c) DIABETES; HEALTH PROMOTION, PREVENTION 
INITIATIVES, 
AND
ACCESS.—The 
Secretary, 
acting 
through the Director of the Centers for Disease Control 
and Prevention and the National Diabetes Education Pro-
gram, shall conduct and support programs to educate spe-
cific minority populations through culturally appropriate 
and linguistically appropriate information campaigns and 
initiatives about prevention of, and managing, diabetes. 
‘‘(d) DEFINITION.—For purposes of this section, the 
term ‘minority population’ means a racial and ethnic mi-
nority group, as defined in section 1707.’’. 
SEC. 7503. PROGRAMS TO EDUCATE HEALTH PROVIDERS 
ON THE CAUSES AND EFFECTS OF DIABETES 
IN MINORITY POPULATIONS. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.), as amended by section 7419(d), 
is amended by adding at the end the following: 
‘‘SEC. 399V–12 PROGRAMS TO EDUCATE HEALTH PRO-
VIDERS ON THE CAUSES AND EFFECTS OF DI-
ABETES IN MINORITY POPULATIONS. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Administrator of the Health Resources and Services 
Administration, shall conduct and support programs de-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01322
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1323 
scribed in subsection (b) to educate health professionals 
on the causes and effects of diabetes in minority popu-
lations. 
‘‘(b) PROGRAMS.—Programs described in this sub-
section, with respect to education on diabetes in minority 
populations, shall include the following: 
‘‘(1) Giving priority, under the primary care 
training and enhancement program under section 
747— 
‘‘(A) to awarding grants to focus on or ad-
dress diabetes; and 
‘‘(B) to adding minority populations to the 
list of vulnerable populations that should be 
served by such grants. 
‘‘(2) Providing additional funds for the Health 
Careers Opportunity Program and the Centers of 
Excellence to partner with the Office of Minority 
Health under section 1707 and the National Insti-
tutes of Health to strengthen programs for career 
opportunities focused on diabetes treatment and care 
within underserved regions highly impacted by dia-
betes. 
‘‘(3) Developing a diabetes focus within, and 
providing additional funds for, the National Health 
Service Corps scholarship program— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01323
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1324 
‘‘(A) to place individuals in areas that are 
disproportionately affected by diabetes and to 
provide diabetes treatment and care in such 
areas; and 
‘‘(B) to provide such individuals continuing 
medical education specific to diabetes care.’’. 
SEC. 7504. RESEARCH, EDUCATION, AND OTHER ACTIVITIES 
REGARDING DIABETES IN AMERICAN INDIAN 
POPULATIONS. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.), as amended by section 7503, 
is amended by adding at the end the following: 
‘‘SEC. 399V–13. RESEARCH, EDUCATION, AND OTHER ACTIVI-
TIES REGARDING DIABETES IN AMERICAN IN-
DIAN POPULATIONS. 
‘‘In addition to activities under sections 317X, 399V– 
12, and 434B, the Secretary, acting through the Indian 
Health Service and in collaboration with other appropriate 
Federal agencies, shall— 
‘‘(1) conduct and support research and other 
activities with respect to diabetes; and 
‘‘(2) coordinate the collection of data on clini-
cally and culturally appropriate diabetes treatment, 
care, prevention, and services by health care profes-
sionals to the American Indian population.’’. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01324
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1325 
SEC. 7505. UPDATED REPORT ON HEALTH DISPARITIES. 
The Secretary of Health and Human Services shall 
seek to enter into an arrangement with the National Acad-
emy of Medicine under which the National Academy will— 
(1) not later than 1 year after the date of en-
actment of this Act, submit to Congress an updated 
version of the 2003 report entitled ‘‘Unequal Treat-
ment: Confronting Racial and Ethnic Disparities in 
Health Care’’; and 
(2) in such updated version, address how racial 
and ethnic health disparities have changed since the 
publication of the original report. 
Subtitle G—Lung Disease 
SEC. 7601. ASTHMA-RELATED ACTIVITIES OF THE CENTERS 
FOR DISEASE CONTROL AND PREVENTION. 
Section 317I of the Public Health Service Act (42 
U.S.C. 247b–10) is amended to read as follows: 
‘‘SEC. 317I. ASTHMA-RELATED ACTIVITIES OF THE CENTERS 
FOR DISEASE CONTROL AND PREVENTION. 
‘‘(a) PROGRAM FOR PROVIDING INFORMATION AND 
EDUCATION
TO
THE PUBLIC.—The Secretary, acting 
through the Director of the Centers for Disease Control 
and Prevention, shall collaborate with State and local 
health departments to conduct activities, including the 
provision of information and education to the public, re-
garding asthma including— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01325
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1326 
‘‘(1) deterring the harmful consequences of un-
controlled asthma; and 
‘‘(2) disseminating health education and infor-
mation regarding prevention of asthma episodes and 
strategies for managing asthma. 
‘‘(b) DEVELOPMENT OF STATE ASTHMA PLANS.— 
The Secretary, acting through the Director of the Centers 
for Disease Control and Prevention, shall collaborate with 
State and local health departments to develop State plans 
incorporating public health responses to reduce the burden 
of asthma, particularly regarding disproportionately af-
fected populations. 
‘‘(c) COMPILATION OF DATA.—The Secretary, acting 
through the Director of the Centers for Disease Control 
and Prevention, shall, in cooperation with State and local 
public health officials— 
‘‘(1) conduct asthma surveillance activities to 
collect data on the prevalence and severity of asth-
ma, the effectiveness of public health asthma inter-
ventions, and the quality of asthma management, in-
cluding— 
‘‘(A) collection of data among people with 
asthma to monitor the impact on health and 
quality of life; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01326
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1327 
‘‘(B) surveillance of health care facilities; 
and 
‘‘(C) collection of data not containing indi-
vidually identifiable information from electronic 
health records or other electronic communica-
tions; 
‘‘(2) compile and annually publish data regard-
ing the prevalence and incidence of childhood asth-
ma, the child mortality rate, and the number of hos-
pital admissions and emergency department visits by 
children associated with asthma nationally and in 
each State and at the county level by age, sex, race, 
and ethnicity, as well as lifetime and current preva-
lence; and 
‘‘(3) compile and annually publish data regard-
ing the prevalence and incidence of adult asthma, 
the adult mortality rate, and the number of hospital 
admissions and emergency department visits by 
adults associated with asthma nationally and in each 
State and at the county level by age, sex, race, eth-
nicity, industry, and occupation, as well as lifetime 
and current prevalence. 
‘‘(d) COORDINATION OF DATA COLLECTION.—The 
Director of the Centers for Disease Control and Preven-
tion, in conjunction with State and local health depart-
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01327
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1328 
ments, shall coordinate data collection activities under 
paragraphs (2) and (3) of subsection (c) so as to maximize 
comparability of results. 
‘‘(e) COLLABORATION.— 
‘‘(1) IN GENERAL.—The Centers for Disease 
Control and Prevention may collaborate with na-
tional, State, and local nonprofit organizations to 
provide information and education about asthma, 
and to strengthen such collaborations when possible. 
‘‘(2) SPECIFIC
ACTIVITIES.—The Director of 
the Centers for Disease Control and Prevention, act-
ing through the Division of Population Health of the 
Centers, may expand activities relating to asthma 
with non-Federal partners, especially State-level en-
tities. 
‘‘(f) REPORTS TO CONGRESS.— 
‘‘(1) IN
GENERAL.—Not later than 3 years 
after the date of the enactment of the Health Equity 
and Accountability Act of 2024, and once 2 years 
thereafter, the Secretary shall, in consultation with 
patient groups, nonprofit organizations, medical so-
cieties, and other relevant governmental and non-
governmental entities, submit to Congress a report 
that— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01328
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1329 
‘‘(A) catalogs, with respect to asthma pre-
vention, management, and surveillance— 
‘‘(i) the activities of the Federal Gov-
ernment, including an assessment of the 
progress of the Federal Government and 
States, with respect to achieving the goals 
of the Healthy People 2030 initiative; and 
‘‘(ii) the activities of other entities 
that participate in the program under this 
section, including nonprofit organizations, 
patient advocacy groups, and medical soci-
eties; and 
‘‘(B) makes recommendations for the fu-
ture direction of asthma activities, in consulta-
tion with researchers from the National Insti-
tutes of Health and other member bodies of the 
Asthma Disparities Subcommittee, including— 
‘‘(i) a description of how the Federal 
Government may improve its response to 
asthma, including identifying any barriers 
that may exist; 
‘‘(ii) a description of how the Federal 
Government may continue, expand, and 
improve its private-public partnerships 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01329
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1330 
with respect to asthma, including identi-
fying any barriers that may exist; 
‘‘(iii) identification of steps that may 
be taken to reduce the— 
‘‘(I) morbidity, mortality, and 
overall prevalence of asthma; 
‘‘(II) financial burden of asthma 
on society; 
‘‘(III) burden of asthma on dis-
proportionately affected areas, par-
ticularly those in medically under-
served populations (as defined in sec-
tion 330(b)(3)); and 
‘‘(IV) burden of asthma as a 
chronic disease that can be worsened 
by environmental exposures; 
‘‘(iv) the identification of programs 
and policies that have achieved the steps 
described under clause (iii), and steps that 
may be taken to expand such programs 
and policies to benefit larger populations; 
and 
‘‘(v) recommendations for future re-
search and interventions. 
‘‘(2) SUBSEQUENT REPORTS.— 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01330
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1331 
‘‘(A) CONGRESSIONAL REQUEST.—During 
the 5-year period following the submission of 
the second report under paragraph (1), the Sec-
retary shall submit updates and revisions of the 
report upon the request of the Congress. 
‘‘(B) FIVE-YEAR REEVALUATION.—At the 
end of the 5-year period referred to in subpara-
graph (A), the Secretary shall— 
‘‘(i) evaluate the analyses and rec-
ommendations made in previous reports; 
and 
‘‘(ii) determine whether an additional 
report is needed and if so submit such an 
updated report to the Congress, including 
appropriate recommendations. 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS FUND-
ING.—In addition to any other authorization of appropria-
tions that is available to the Centers for Disease Control 
and Prevention for the purpose of carrying out this sec-
tion, there is authorized to be appropriated to such Cen-
ters $65,000,000 for the period of fiscal years 2025 
through 2029 for the purpose of carrying out this sec-
tion.’’. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01331
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1332 
SEC. 7602. INFLUENZA AND PNEUMONIA VACCINATION 
CAMPAIGN. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall— 
(1) enhance the annual campaign by the De-
partment of Health and Human Services to increase 
the number of people vaccinated each year for influ-
enza and pneumonia; and 
(2) include in such campaign the use of written 
educational materials, public service announcements, 
physician education, and any other means which the 
Secretary determines effective. 
(b) MATERIALS AND ANNOUNCEMENTS.—In carrying 
out the annual campaign described in subsection (a), the 
Secretary of Health and Human Services shall ensure 
that— 
(1) educational materials and public service an-
nouncements are readily and widely available in 
communities experiencing disparities in the incidence 
and mortality rates of influenza and pneumonia; and 
(2) the campaign uses targeted, culturally ap-
propriate messages and messengers to reach under-
served communities. 
(c) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01332
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1333 
such sums as may be necessary for each of fiscal years 
2025 through 2029. 
SEC. 7603. CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 
(a) IN GENERAL.—The Director of the Centers for 
Disease Control and Prevention shall conduct, support, 
and expand public health strategies and prevention, diag-
nosis, surveillance, and public and professional awareness 
activities regarding chronic obstructive pulmonary disease. 
(b) CHRONIC DISEASE PREVENTION PROGRAMS.— 
The Director of the National Heart, Lung, and Blood In-
stitute shall carry out the following: 
(1) Conduct public education and awareness ac-
tivities with patient and professional organizations 
to stimulate earlier diagnosis and improve patient 
outcomes from treatment of chronic obstructive pul-
monary disease. To the extent known and relevant, 
such public education and awareness activities shall 
reflect differences in chronic obstructive pulmonary 
disease by cause (tobacco, environmental, occupa-
tional, biological, and genetic) and include a focus 
on outreach to undiagnosed and, as appropriate, mi-
nority populations. 
(2) Supplement and expand upon the activities 
of the National Heart, Lung, and Blood Institute by 
making grants to nonprofit organizations, State and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01333
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1334 
local jurisdictions, and Indian Tribes for the purpose 
of reducing the burden of chronic obstructive pul-
monary disease, especially in disproportionately im-
pacted communities, through public health interven-
tions and related activities. 
(3) Coordinate with the Centers for Disease 
Control and Prevention, the Indian Health Service, 
the Health Resources and Services Administration, 
and the Department of Veterans Affairs to develop 
pilot programs to demonstrate best practices for the 
diagnosis and management of chronic obstructive 
pulmonary disease. 
(4) Develop improved techniques and identify 
best practices, in coordination with the Secretary of 
Veterans Affairs, for assisting chronic obstructive 
pulmonary disease patients to successfully stop 
smoking, including identification of subpopulations 
with different needs. Initiatives under this para-
graph may include research to determine whether 
successful smoking cessation strategies are different 
for chronic obstructive pulmonary disease patients 
compared to such strategies for patients with other 
chronic diseases. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01334
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1335 
(c) ENVIRONMENTAL AND OCCUPATIONAL HEALTH 
PROGRAMS.—The Director of the Centers for Disease 
Control and Prevention shall— 
(1) support research into the environmental and 
occupational causes and biological mechanisms that 
contribute to chronic obstructive pulmonary disease; 
and 
(2) develop and disseminate public health inter-
ventions that will lessen the impact of environmental 
and occupational causes of chronic obstructive pul-
monary disease. 
(d) DATA COLLECTION.—Not later than 180 days 
after the date of enactment of this Act, the Director of 
the National Heart, Lung, and Blood Institute and the 
Director of the Centers for Disease Control and Preven-
tion, acting jointly, shall assess the depth and quality of 
information on chronic obstructive pulmonary disease that 
is collected in surveys and population studies conducted 
by the Centers for Disease Control and Prevention, includ-
ing whether there are additional opportunities for informa-
tion to be collected in the National Health and Nutrition 
Examination Survey, the National Health Interview Sur-
vey, and the Behavioral Risk Factors Surveillance System 
surveys. 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01335
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1336 
(e) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of fiscal years 
2025 through 2029. 
Subtitle H—Tuberculosis 
SEC. 7701. UNITED STATES GOVERNMENT ASSISTANCE TO 
COMBAT TUBERCULOSIS. 
Section 104B of the Foreign Assistance Act of 1961 
(22 U.S.C. 2151b–3) is amended to read as follows: 
‘‘SEC. 104B. ASSISTANCE TO COMBAT TUBERCULOSIS. 
‘‘(a) POLICY.— 
‘‘(1) IN GENERAL.—It is a major objective of 
the foreign assistance program of the United States 
to help end the TB public health emergency through 
accelerated actions— 
‘‘(A) to support the diagnosis and treat-
ment of all adults and children with all forms 
of TB; and 
‘‘(B) to prevent new TB infections from 
occurring. 
‘‘(2) SUPPORT FOR GLOBAL PLANS AND OBJEC-
TIVES.—In countries in which the United States 
Government has established foreign assistance pro-
grams under this Act, particularly in countries with 
the highest burden of TB and other countries with 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01336
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1337 
high rates of infection and transmission of TB, it is 
the policy of the United States— 
‘‘(A) to support the objectives of the World 
Health Organization End TB Strategy, includ-
ing its goals— 
‘‘(i) to reduce TB deaths by 95 per-
cent by 2035; 
‘‘(ii) to reduce the TB incidence rate 
by 90 percent by 2035; and 
‘‘(iii) to reduce the number of families 
facing catastrophic health costs due to TB 
by 100 percent by 2035; 
‘‘(B) to support the Stop TB Partnership’s 
Global Plan to End TB 2023–2030, including 
by providing support for— 
‘‘(i) developing and using innovative 
new technologies and therapies to increase 
active case finding and rapidly diagnose 
and treat children and adults with all 
forms of TB, alleviate suffering, and en-
sure TB treatment completion; 
‘‘(ii) expanding diagnosis and treat-
ment in line with the goals established by 
the Political Declaration of the High-Level 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01337
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1338 
Meeting of the General Assembly on the 
Fight Against Tuberculosis, including— 
‘‘(I) 
successfully 
treating 
40,000,000 people with active TB by 
2023, including 3,500,000 children, 
and 1,500,000 people with drug-re-
sistant TB; and 
‘‘(II) diagnosing and treating la-
tent tuberculosis infection, in support 
of the global goal of providing preven-
tive therapy to at least 30,000,000 
people by 2023, including 4,000,000 
children younger than 5 years of age, 
20,000,000 household contacts of peo-
ple affected by TB, and 6,000,000 
people living with HIV; 
‘‘(iii) ensuring high-quality TB care 
by closing gaps in care cascades, imple-
menting continuous quality improvement 
at all levels of care, and providing related 
patient support; and 
‘‘(iv) sustainable procurements of TB 
commodities to avoid interruptions in sup-
ply, the procurement of commodities of un-
known quality, or payment of excessive 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01338
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1339 
commodity costs in countries impacted by 
TB; and 
‘‘(C) to ensure, to the greatest extent prac-
ticable, that United States funding supports ac-
tivities that simultaneously emphasize— 
‘‘(i) the development of comprehensive 
person-centered programs, including diag-
nosis, treatment, and prevention strategies 
to ensure that— 
‘‘(I) all people sick with TB re-
ceive quality diagnosis and treatment 
through active case finding; and 
‘‘(II) people at high risk for TB 
infection are found and treated with 
preventive therapies in a timely man-
ner; 
‘‘(ii) robust TB infection control prac-
tices are implemented in all congregate set-
tings, including hospitals and prisons; 
‘‘(iii) the deployment of diagnostic 
and treatment capacity— 
‘‘(I) in areas with the highest TB 
burdens; and 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01339
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1340 
‘‘(II) for highly at-risk and im-
poverished populations, including pa-
tient support services; 
‘‘(iv) program monitoring and evalua-
tion based on critical TB indicators, in-
cluding indicators relating to infection con-
trol, the numbers of patients accessing TB 
treatment and patient support services, 
and preventative therapy for those at risk, 
including all close contacts, and treatment 
outcomes for all forms of TB; 
‘‘(v) training and engagement of 
health care workers on the use of new di-
agnostic tools and therapies as they be-
come available, and increased support for 
training frontline health care workers to 
support expanded TB active case finding, 
contact tracing, and patient support serv-
ices; 
‘‘(vi) coordination with domestic agen-
cies and organizations to support an ag-
gressive research agenda to develop vac-
cines as well as new tools to diagnose, 
treat, and prevent TB globally; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01340
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS
1341 
‘‘(vii) linkages with the private sector 
on— 
‘‘(I) research and development of 
a vaccine, and on new tools for diag-
nosis and treatment of TB; 
‘‘(II) improving current tools for 
diagnosis and treatment of TB, in-
cluding telehealth solutions for pre-
vention and treatment; and 
‘‘(III) training healthcare profes-
sionals on use of the newest and most 
effective diagnostic and therapeutic 
tools; 
‘‘(viii) the reduction of barriers to 
care, including stigma and treatment and 
diagnosis costs, including through— 
‘‘(I) training health workers; 
‘‘(II) sensitizing policy makers; 
‘‘(III) requiring that all relevant 
grants and funding agreements in-
clude access and affordability provi-
sions; 
‘‘(IV) supporting education and 
empowerment campaigns for TB pa-
tients regarding local TB services; 
VerDate Sep 11 2014 
20:45 Sep 11, 2024
Jkt 049200
PO 00000
Frm 01341
Fmt 6652
Sfmt 6201
E:\BILLS\H9161.IH
H9161
ssavage on LAPJG3WLY3PROD with BILLS